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 Characterization of the BACH1 helicase in the DNA damage response pathway 
 
ABSTRACT 
 
DNA damage response pathways are a complicated network of proteins that 
function to remove and/or reverse DNA damage.  Following genetic insult, a signal 
cascade is generated, which alerts the cell to the presence of damaged DNA.  Once 
recognized, the damage is either removed or the damaged region is excised, and the 
original genetic sequence is restored.  However, when these pathways are defective the 
cell is unable to effectively mediate the DNA damage response and the damage persists 
unrepaired.  Thus, the proteins that maintain the DNA damage response pathway are 
critical in preserving genomic stability. 
One essential DNA repair protein is the Breast Cancer Associated gene, BRCA1.  
BRCA1 is essential for mediating the DNA damage response, facilitating DNA damage 
repair, and activating key cell cycle checkpoints.  Moreover, mutations in BRCA1 lead to 
a higher incidence of breast and ovarian cancer, highlighting the importance of BRCA1 
as a tumor suppressor.  In an effort to better understand how BRCA1 carried out these 
functions, researchers sought to identify additional BRCA1 interacting proteins.   This led 
to the identification of several proteins including the BRCA1 Associated C-terminal 
Helicase, BACH1.  Due to the direct interaction of BACH1 with a region of BRCA1 
essential for DNA repair and tumor suppression, it was speculated that BACH1 may help 
support these BRCA1 function(s). In fact, initial genetic screenings confirmed that 
 
 x
mutations in BACH1 correlated not only with hereditary breast cancer, but also with 
defects in DNA damage repair processes.   
The initial correlation between BACH1 and cancer predisposition was further 
confirmed when mutations in BACH1 were identified in the cancer syndrome Fanconi 
anemia (FA) (complementation group FA-J), thus giving BACH1 its new name FANCJ.   
These findings supported a previously established link between the FA and BRCA 
pathways and between FA and DNA repair.  In particular, we demonstrated that similar 
to other FA/BRCA proteins, suppression of FANCJ lead to a substantial decrease in 
homologous recombination and enhanced both the cellular sensitivity to DNA interstrand 
cross-linking agents and chromosomal instability.  What remained unknown was 
specifically how FANCJ functioned and whether these functions were dependent on its 
interaction with BRCA1 or other associated partners.   In fact, we identified that FANCJ 
interacted directly with the MMR protein MLH1.  Moreover, we found that the 
FANCJ/BRCA1 interaction was not required to correct the cellular defects in FA-J cells, 
but rather that the FANCJ/MLH1 interaction was required.  Although both the FA/BRCA 
and MMR pathways undoubtedly mediate the DNA damage response, there was no 
evidence to suggest that these pathways were linked, until recently.  Our findings not 
only indicate a physical link between these pathways by protein-protein interaction, but 
also demonstrated a functional link. 
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CHAPTER I 
 
INTRODUCTION 
 
DNA DAMAGE RESPONSE 
Cells are constantly under attack from both endogenous and exogenous forms of 
DNA damage.  Endogenous DNA damage can be accrued by cellular metabolic processes 
including release of oxygen free radicals, base hydrolysis, and cytosine deamination.  
Similarly, exogenous DNA damage can be inflicted on the genome by environmental 
factors such as exposure to ultraviolet radiation (UV) and/or ionizing radiation (IR).  
Collectively, these forms of DNA damage are a threat to both cell viability and to 
genomic stability.  Thus, cells have evolved intricate mechanisms to sense damaged DNA 
and signal a DNA damage response 1.  
 The DNA damage response can be initiated by any of several mechanisms 
including changes in chromatin structure, protein modification/activation/relocalization, 
and/or generation of single stranded DNA (ssDNA).  Once the DNA damage signal is 
initiated and amplified, the cell activates cell cycle checkpoints to arrest cell cycle 
progression, and/or repair pathways. If the damage is irreparable, the cell can activate an 
apoptotic response and induce cell death 2.  Thus, the proteins regulating cell cycle 
checkpoints, DNA damage repair, and apoptosis function in a coordinated manner to 
preserve both cell viability and genetic integrity.    
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The DNA damage induced checkpoints function to arrest cell cycle progression at 
the G1/S, intra-S, and/or G2/M checkpoints. Checkpoint activation is regulated by 
proteins, which can be categorized as sensors, mediators, transducers, and/or effectors.   
The sensory proteins are responsible for recognizing DNA damage either directly and/ or 
indirectly.  Mediators facilitate the propagation of the damage signal by bridging the 
activated sensor proteins to specific signal transduction proteins.  These transduction 
proteins generally consist of protein kinases and phosphatases, which function to activate, 
or inactivate, the effector proteins.  It is the effector proteins that function to directly 
regulate cell cycle progression 2,3. 
DNA damage-signaling and activation of cell cycle checkpoints are essential for 
efficient DNA damage repair.  If damage is not repaired before subsequent rounds of cell 
division the daughter cells can acquire genetic mutations.  Therefore, the cell has several 
distinct repair pathways to remove, or reverse, specific types of DNA modifications.  
Cells containing mutations in genes involved in the DNA damage response pathway 
become increasingly mutagenic and consequently, lose the ability to govern cell growth 
and/or proficient repair, enhancing the possibility of tumorigenesis 2,3. 
Not surprisingly, defects in DNA damage response, checkpoint, and/or repair are 
intimately linked to cancer susceptibility 4.  For example, mutations in BRCA1, lead to 
defects in DNA damage response, checkpoint, and repair. To further understand the role 
of BRCA1 in the damage response and tumor suppression, research was directed at 
identifying BRCA1 interacting proteins (Figure 1-1). This effort led to the identification 
of several BRCA1 interacting proteins, including BACH1 5.   Further studies found 
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germline mutations in BACH1, in patients with early onset breast cancer 6 7.  Moreover, 
BACH1 was shown to be required for efficient DNA double strand break repair (DSBR) 
in a BRCA1 dependent manner 6.  The aim of this thesis was to further characterize the 
function of BRCA1 and BACH1 in the DNA damage response and to develop our 
understanding of how these proteins function as tumor suppressors.  To better appreciate 
the function of these proteins in the DNA damage response and tumor suppression, it is 
essential to have a basic understanding of how cells respond to different forms of DNA 
damage.  
 
DNA DAMAGE REPAIR 
DNA damaging agents are capable of inducing a range of DNA modifications.  
However, it is the most severe modifications, such as DSBs that threaten the overall 
viability of a healthy cell.  Double stranded DNA breaks (DSB(s)) can be generated 
directly by DNA damage (i.e. IR) or by the processing of damaged genetic elements (i.e. 
processing of alkylating agents).  If left unrepaired, these breaks threaten the overall 
stability of the genome and basic cell survival 1.    
 
DNA modifications 
DNA damage can be generated by several different agents.  For example x-rays, 
alpha/beta/gamma rays, and neutrons are all forms of IR that can create a charge 
separation in medium.  IR can damage cells both directly and indirectly depending on 
how the cellular components absorb the radiation particles.   
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Figure 1-1: Established BRCA1 functions. The BRCA1 protein is characterized as both 
a tumor suppressor and a DNA damage response protein critical for mediating cell cycle 
checkpoints and DNA damage repair.  These functions are compromised by mutations in 
the C-terminal BRCT repeats of BRCA1 suggesting that this region was critical for 
maintaining BRCA1 function.   
 
Checkpoint? 
DNA Damage 
Sensitivity? 
Chromosome 
Instability? 
DNA Damage Repair? 
                BRCA1 
Cancer Predisposition? 
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If the molecules within the cell absorb the radiation, an ionization reaction may result and 
produce electrophilic species.  In a secondary or indirect reaction, these species are then 
capable of attacking DNA molecules and subsequently, induce a variety of genetic 
lesions.   
Alternatively, the radiation particles can be directly absorbed by the DNA itself, 
resulting in the ionization of bases and/or the sugar phosphate backbone 1,8.  Collectively, 
indirect and direct ionizing radiations are capable of inducing a range of DNA 
modifications, however it is the formation of the DSB that is most toxic 1.    
 In some cases, as with direct absorption of IR particles, the initial lesion is a 
DSB.  Alternatively a DSB may be generated after a primary lesion is processed.  For 
example, the processing of DNA crosslinks can lead to the formation of a DSB.  DNA 
crosslinks can be introduced into DNA endogenously by the acidification of nitrites 
during cellular metabolism 1,9,10 or exogenously by several classes of DNA crosslinking 
agents including nitrogen mustards (Melphalan), platinum drugs (Cisplatin), and the 
natural alkylating agent Mitomycin C (MMC) 10.   Complex chemical analyses have 
demonstrated that MMC and Melphalan are bifunctional DNA alkylating agents that 
predominantly result in the formation of DNA interstrand crosslinks (ICLs) 11.  As a 
consequence of DNA crosslinks, the separation of complementary DNA strands during 
DNA replication and transcription is inhibited. Thus, removing ICLs is critical for cell 
survival 1,2,11.  Removal of a DNA crosslink involves several repair mechanisms that are 
required for recognition and removal of the ICL followed by restoration of the original 
genetic sequence.  The DNA crosslink may be initially recognized by replication 
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machinery actively synthesizing new DNA.  When the ICL lesion is encountered, 
replication is arrested and the replication fork is stabilized to allow the repair machinery 
access to the damage site.  At this time the ICL can be excised and a DSB may be 
formed, thus, it is the initial processing of the ICL that result in the formation of the toxic 
DSB 1.   
Likewise, the processing of DNA methylation adducts also results in the 
formation of DSBs.  DNA methylation is the covalent addition of a methyl group to a 
nucleophilic species within the DNA molecule.  Although this can occur at any position 
within the DNA molecule, typically, the cyclic nitrogen and oxygen atoms are the most 
reactive.  Methyl compounds are formed both endogenously as products of cellular 
metabolism and also introduced exogenously as chemically synthesized compounds 1,12.  
One commonly used chemical compound is N-methyl-N-nitrosurea (MNU).  MNU is an 
SN1 type monofunctional methylating agent that is highly reactive to oxygen molecules 
within DNA.  The major adduct formed by MNU following cellular exposure, is O6 
methylguanine (O6 MeG) 12.  Generally, the methylguanine methyltransferase (MGMT) 
enzyme functions to remove the O6methyl adduct from the DNA prior to replication.  
However, in colon and other types of cancer expression of MGMT is frequently silenced 
by promoter hypermethylation 13.   Consequently, during DNA replication, the O6 MeG is 
interpreted as an adenine and is paired with a thymine, resulting in a GT mispair.  If the 
mismatch is left unrepaired in the genome subsequent rounds of replication produce a 
GC-TA transition mutation.  If the mismatch is repaired, the misincorporated base is 
excised and the replication machinery will inherently resynthesize DNA at the damaged 
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site.  However, the methylated base will again be misread and the replication machinery 
incorporates a T across from the O6 MeG, beginning a futile cycle of repair.  If this site of 
misincorporation is across from another site of misincorporation, an Okazaki fragment, or 
the leading strand of replication a DSB can be formed  13.  
 
Repair of double stranded DNA breaks    
 One of the early events following cellular exposure to DNA damage is the 
phosphorylation of the histone variant γH2AX 14.  γH2AX represents the presence of 
DSBs and has been demonstrated to be within 1-2kb of the break site 15.  In eukaryotes 
there are two major pathways for repair of DSBs, homologous recombination (HR) and 
non-homologous end-joining (NHEJ).  While NHEJ is an error prone pathway and results 
in the loss of genetic information, HR repair is error-free and generally restores the 
original sequence.  HR requires either a homologous sister chromatid, or homologous 
chromosome, with identical sequence to serve as a template for accurate repair.  Thus, the 
HR repair pathway not only repairs DNA damage, but also restores the original genetic 
information (Figure 1-2) 16.   
The initial processing of the DSB for HR requires the formation of a single 
stranded DNA region at the site of the break.  Here, the 5’ strand of the duplex is resected 
and leaves a 3’ single-stranded DNA region.  This 3’ DNA overhang is initially stabilized 
by the single-stranded binding protein RPA, but is then replaced by the RAD51 
recombination protein forming a nucleoprotein filament.  The RAD51 nucleoprotein 
filament searches for a region of sequence homology on either a sister chromatid or a 
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homologous chromosome and forms a paranemic joint.  Once the nucleoprotein filament 
aligns with a homologous sequence and strand exchange occurs, new DNA is synthesized 
at the broken ends, and a heteroduplex DNA intermediate, or Holliday junction, is 
formed.  Following endonucleolytic cleavage the Holliday junction is resolved and the 
original break has been repaired with no loss of genetic information 17. 
 
DNA DAMAGE RESPONSE PATHWAYS AND CANCER 
 
The link between the FA/BRCA pathway and cancer 
Defects in DSBR and/or pathways that help promote HR contribute to the 
development of cancer 4.  In particular, inherited genetic mutations in genes of the 
Fanconi anemia (FA)/BRCA pathway leads to reduced HR in response to DSBs and 
ultimately compromises cell survival.  Specifically, cells from patients with FA are 
hypersensitive to DNA crosslinking agents such as cisplatin, MMC, melphalan, and 
diepoxybutane (DEB).  Following exposure to any one of these clastogens, FA cells 
demonstrate defects in cell cycle progression and demonstrate gross chromosomal 
instability 18. Given these defects, it is not surprising that in addition to aplastic anemia 
and congenital abnormalities, FA is characterized by increased cancer susceptibility.       
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Figure 1-2: Schematic representation of homologous recombination.  DNA damage 
can result in the formation of a double-stranded break.  The schematic below depicts the 
mechanism used to repair a DSB by HR.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
      Adapted from Sung and Klein Nature Reviews Molecular Cell Biology 7, 739–750 (October 2006). 
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In an attempt to understand the correlation between FA defects and cancer, 
researchers sought to identify the gene defects in each of the patient complementation 
groups. To date, 12 FA complementation groups (FA-A, FA-B, FA-C, FA-D1, FA-D2, 
FA-E, FA-F, FA-G, FA-I, FA-J, FA-L, FA-M) have been identified and 11 of the 
corresponding genes have been cloned (all except FA-I). Each of the complementation 
groups is distinct and the genes do not share sequence homology.  Since their 
identification, research has provided insight towards the function of several of these 
proteins within the FA pathway. The central feature of the FA pathway is the 
monoubiquitination of the FANCD2 protein by the FA core complex (FA-A, FA-B, FA-
C, FA-E, FA-F, FA-G, FA-L, FA-M).  This event is required for FANCD2 chromatin 
localization and accumulation in nuclear foci suggesting that FANCD2 aggregates at sites 
of DNA damage to mediate the DNA damage response and ultimately promote error-free 
repair (Figure 1-3) 18. 
           One of the first clues to the function of the FA pathway was provided by its 
similarity to the BRCA pathway.  Specifically, the correlation between FA and BRCA 
cellular phenotypes suggested that these two pathways were directly connected.   Loss of 
either FA proteins, or BRCA proteins, conferred cellular sensitivity to DNA damaging 
agents, defects in cell cycle checkpoints, and gross chromosomal abnormalities 19-21. 
Subsequent sequencing data identified that the FA-D1 gene defect was, in fact, the result 
of a biallelic mutation in the breast cancer susceptibility gene, BRCA2 22.  Subsequently, 
FA-D1 is now referred to as BRCA2/FANCD1.  Further linking the two pathways, was 
the initial finding that BRCA1 was the E3 ubiquitin ligase responsible for 
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monoubiquitination of FANCD2.  Initial studies conducted in vitro, suggested that the 
BRCA1/BARD1 E3 complex was sufficient to monoubiquitinate FANCD2.  This 
hypothesis was further supported by studies conducted in HCC1937 cells, lacking 
functional BRCA1 23.  However, it was later found that this result could not be 
reproduced in multiple cell lines, clouding the role of BRCA1 in this process.  Current 
data supports the finding that FANCL is actually the E3 ubiquitin ligase required for 
FANCD2 monoubiquitination 24.    
          Although BRCA1 does not appear to be required for FANCD2 
monoubiquitination, BRCA1 is required for the proper DNA damage-induced 
localization of FANCD2 23,25.  Moreover, the similarity between BRCA1 and FA 
deficient cells further suggests that BRCA1 is linked to this pathway.  Finally, research 
demonstrated that BRCA1 formed a direct interaction with BACH1 and that this 
interaction was critical for DSB repair.  We later identified that BACH1 was the gene 
defect in the FA-J complementation group (referred to now as FANCJ) and once again 
provided evidence of BRCA1’s involvement in the FA pathway (see chapter 3).   
 
The FA/BRCA pathway DNA damage response 
The phosphatidylinositol 3-kinases Ataxia Telangiectasia mutated kinase (ATM) and the 
ATM Rad3 Related kinase (ATR) are initial responders and activators of the FA/BRCA 
pathway 3,26,27.  Following genotoxic stress these kinases are activated and transduce the 
DNA damage signal downstream to a number of FA proteins, regulating their function(s) 
28. 
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Figure 1-3: Cartoon of the FA/BRCA pathway.  Following DNA damage, FANCD2 is 
monoubiquitinated by the FA core complex and translocates into chromatin where it 
colocalizes in nuclear foci with FANCJ, BRCA1, and BRCA2/FANCD1.  
Monoubiquitination of FANCD2 is critical for maintaining normal cell cycle progression 
and effective DNA damage repair. 
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  In particular, ATM phosphorylates FANCD2 at multiple residues in vivo, including 
S222, S1401, S1404, and S1418.  However, it is the phosphorylation event at residue 
S222 that is critical for activation of the IR-induced intra-S-phase checkpoint 27,29.  Like 
ATM, ATR has also been shown to phosphorylate FANCD2 at several residues 
including, T691, S717, S222, S1401, S1404, and S1418.  Phosphorylation at residues 
T691 and S717 enhances FANCD2 monoubiquitination, increases cellular resistance to 
MMC, and is required for activation of the ICL-induced intra-S-phase checkpoint 29. 
ATR is also essential for the DNA damage-induced FANCD2 monoubiquitination 
26.  Ubiquitination is a tightly regulated process and governs a multitude of pathways.  In 
some instances, proteins are covalently modified with multiple ubiquitin moieties 
forming a polyubiquitin chain.  This chain functions as a signal, flagging the modified 
protein for degradation by the proteosome.  However, in other instances such as with 
FANCD2, a single ubiquitin moiety is added and here the modification acts as a signal 
activating the FA pathway 30.  Following monoubiquitination, FANCD2 translocates into 
chromatin and is targeted to nuclear foci containing a number of DNA damage proteins 
including ATR, RPA, FANCE, FANCC, NBS1, BLM, FANCJ, BRCA1, BRCA2, and 
RAD51 18.  Furthermore, in response to DNA damage many FA proteins form distinct 
protein-protein interactions.  In particular, FANCD2 interacts with FANCE, 
BRCA2/FANCD1, and BRCA1 in chromatin and supports the hypothesis that FANCD2 
regulates the process of recombination 31,32.    
The DNA damage-induced monoubiquitination of FANCD2 is regulated by the 
FA core complex members FA-A, FA-B, FA-C, FA-E, FA-F, FA-G, FA-L, and FA-M.  
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This complex is required for the monoubiquitination of FANCD2 during S-phase of the 
cell cycle and following cellular exposure to DNA damaging agents 18.  Further 
characterization has revealed that FA-L is the catalytically active E3 ubiquitin ligase of 
the core subunits and is responsible for ubiquitination, and subsequent activation, of 
FANCD2 at lysine 561 23.  FA-I is required for FANCD2 monoubiquitination, however, 
it is not required for stability of the core complex subunits.  Thus, FA-I appears to 
function upstream of FANCD2 activation, but independent of the core complex 33.  
FANCJ and BRCA2/FANCD1 are not required for FANCD2 monoubiquitination and 
function downstream in the FA pathway (FANCJ see chapter 3) 32.  Monoubiquitination 
of FANCD2 is the central feature of the FA/BRCA pathway and loss of this biochecmical 
transaction inactivates the pathway and abrogates an effective DNA damage response 18.   
 
FA/BRCA proteins and DNA damage repair  
      It is conceivable that the cellular sensitivity of FA/BRCA cells to DNA damaging 
agents results from defects in repair. FA/BRCA proteins have been implicated in 
promoting error-prone repair through non-homologous end joining and single-strand 
annealing, as well as error-free repair through HR 34,35.  The evidence linking FA/BRCA 
proteins to HR, stems from homology directed DSB repair assays (Figure 1-4), 
association with other recombination proteins, and/or loss of Rad51 foci 18. The exact 
role of BRCA1 in HR remains elusive, yet in the absence of BRCA1, RAD51 foci do not 
accumulate and HR is dramatically reduced 36,37.  In contrast, the role of 
BRCA2/FANCD1 in HR has been well-characterized due to its direct interaction with 
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Rad51 38.  The BRCA2/FANCD1 structure suggests that it loads Rad51 onto ssDNA.  In 
particular, BRCA2/FANCD1 contains 8 BRC repeats that are each, approximately 30 
amino acids in length, and span the length of the protein.  These motifs directly interact 
with the RAD51 protein and mediate the formation of a RAD51 nucleoprotein filament, a 
critical step required for strand invasion during HR 39.  At the C-terminus, BRCA2 
contains a helical domain, 3 oligonucleotide/oligosaccharide binding folds, and a tower 
domain.  The oligonucleotide/oligosaccharide binding folds (OB1, OB2, and OB3) and 
the tower domain bind ssDNA and dsDNA, respectively 40.  Moreover, 
BRCA2/FACND1 has been show to function at stalled replication forks to provide 
stability and prevent fork collapse.  Taken together, the structural components of BRCA2 
support the notion that BRCA2/FACND1 binds single-stranded/double-stranded DNA 
regions (i.e., resected end at DSB site or at stalled replication forks) and loads RAD51 
protein, promoting HR and maintaining genomic integrity.   
BRCA2/FANCD1 is targeted to chromatin following DNA damage where it 
interacts with several FA proteins including FANCD2 and FANCG 18.  
BRCA2/FANCD1 interacts with FANCG through both its N and C-termini.  This 
interaction mediates a ternary complex with the recombination protein XRCC3.  XRCC3 
is a key component in the recombinational repair pathway and facilitates the formation of 
the RAD51 nucleoprotein filament.  FANCG can be coprecipitated with both XRCC3 
and BRCA2 and it has been demonstrated that FANCG serves as a bridge stabilizing the 
complex 41.  It is the interaction between FANCG and the recombination proteins XRCC3 
and BRCA2 that suggests a role for FANCG in homology directed repair. 
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Interestingly, 42 has shown that Fancd2 -/- MEFs can be sensitized to IR by 
suppression of Prkdc, a critical component of the NHEJ pathway.  Prkdc -/- mice are 
characteristically sensitive to IR, however, this sensitivity was increased in the Fancd2 -/- 
Prkdc -/- double mutant MEFs.  The double mutant MEFs also demonstrated an increase 
in radial chromosomes, indicative of defects in DNA damage repair.  Lastly, Fancd2 -/- 
Prkdc -/- double mutant mice had a significant decrease in survival following whole body 
irradiation.  These findings indicate that the FA proteins function in a pathway distinct 
from NHEJ in repair of DNA damage and further support the role of FANCD2 in HR.  
Furthermore, these results suggest that the insensitivity of FA deficient cells to IR may be 
a result of compensation by the NHEJ pathway.  In the absence of both HR and NHEJ the 
cell is unable to utilize two major repair pathways and accrues gross chromosomal 
instability, ultimately compromising cell survival.  
Lastly, FANCA and FANCC have also been associated with HR 35,43,44.  FANCC 
directly interacts with FANCE 45 and forms a ternary complex that includes FANCD2 46.  
FANCC has been speculated to function in concert with both TLS and HR to mediate 
DNA damage repair 44.  The role of FANCA in HR was directly assessed in mammalian 
cell-based homology directed repair assays.  This finding was then supported indirectly 
by cell survival assays utilizing Poly (ADP Ribose) Polymerase (PARP) inhibitors.  
PARP inhibitors suppress the base excision repair pathway and thus, force the cell to 
repair damaged DNA by HR.  Similar to BRCA1 and BRCA2 deficient cells, when FA-A 
cells were treated with PARP inhibitors they demonstrated an increase in cell death 
compared to FA-A cells reconstituted with FANCA suggesting that FANCA is in fact 
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required for effective HR 47.  Taken together, these finding suggests that the functions of 
the core complex proteins are not limited FANCD2 monoubiquitination, but that they 
may extend to early stages of recombination. 
To date, BRCA1, BRCA2/FANCD1, FANCD2, FANCG, FANCA, FANCC, and 
FANCJ (see chapter 3) have all been implicated in the HR repair pathway and loss of any 
one protein demonstrated a decrease in the cells ability to mediate repair by HR.  In 
contrast, FANCC and FANCJ have also been reported to have normal repair functions in 
DT40 chicken cells and FANCD2 cells have demonstrated both normal and aberrant 
repair in FA fibroblasts 18.  The inconsistencies in the data may be attributed to the 
diversity in cell type or the specific homology directed repair substrate used to assess 
repair functions.  Although, there are discrepancies within the literature it appears that 
overall the FA proteins are critical for mediating some aspect of HR repair.  
 
 
FA/BRCA proteins and cell cycle checkpoint 
  
In addition to the role of the FA/BRCA proteins in DNA damage repair, they are 
also critical for maintaining normal cell cycle progression following DNA damage and in 
some cases, activating cell cycle checkpoints 18.  The IR inducible S-phase checkpoint is 
frequently characterized by observing the inhibition of replicative DNA synthesis 
following cellular exposure to IR.  However, cells defective for this checkpoint fail to 
stop DNA synthesis after IR treatment and these cells are said to exhibit radio-resistant 
DNA synthesis, or RDS.   
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Figure 1-4: Schematic representation of the DR-GFP homology directed repair 
substrate.  The DR-GFP substrate is one example of a reporter gene that is commonly 
integrated into mammalian cell lines to analyze the role of DNA damage response 
proteins in HR (see chapter 2 for details). 
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 For example, cells from several FA complementation groups display a substantial RDS 
phenotype including FANCA, BRCA2/FANCD1, and FANCD2 27,48.  Similarly, FANCJ 
and BRCA1 deficient cells also display an RDS phenotype 49.  The function of FANCD2 
in the intra-S-phase checkpoint has been further detailed by mutational analysis.  RDS 
assays using FA-D2 fibroblasts reconstituted with FANCD2 phosphorylation mutants, 
have demonstrated that serine 222, serine 717, and threonine 691 are all critical for 
activation of the S-phase checkpoint 27.  Although other FA complementation groups 
have not been specifically tested in RDS assays, FA proteins were shown to accumulate 
on chromatin during replication initiation and in response to replication induced DNA 
lesions in Xenopus extracts 50 supporting a role for these proteins in regulating S-phase 
progression. 
FA cells have also been characterized by an ICL-induced cell cycle progression 
defect 51.  In response to ICL damage, FA cells undergo growth arrest and a pronounced 
accumulation of cells with 4N DNA content.  Reconstitution of FA cells with the 
appropriate FA complement restores cell growth and drastically reduces the 4N 
accumulation, substantiating the role of the FA proteins in maintaining normal cell cycle 
52.   The true mechanism of this accumulation remains unclear; however, it may represent 
a failure of FA cells to cease DNA synthesis in S-phase after ICL damage.  
Consequently, these cells do not have a chance to repair damaged elements until they 
reach G2/M and thus, show a pronounced 4N accumulation.  Defective inhibition of 
DNA synthesis following ICL treatment has been demonstrated in FA-A, FA-B, FA-C, 
FA-G, FA-D2 cells 53-55.  However, it has also been suggested that the observed 
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accumulation at 4N may truly represent a delay in exit from S-phase and not a defect in 
the intra-S-phase checkpoint 56 (see chapter 4).  FA cells may coordinate the completion 
of DNA repair and exit from S-phase, thus a delay in repair may also delay exit from S-
phase 52,57.   
Although the FA/BRCA proteins are required for normal cell cycle progression 
following DNA damage, it is unclear whether this progression is regulated by activation 
of specific cell cycle checkpoints or dictated by the repair process, or both.  To further 
understand how FANCJ may contribute to these functions we sought to identify FANCJ 
interacting proteins.  Notably, we found that FANCJ formed a stable interaction with the 
mismatch repair protein (MMR), MLH1.  The MMR proteins, including MLH1, have 
been implicated in maintenance of both cell cycle progression and the stringency of 
homology directed recombination.  Just as in FA, mutations in MMR genes are closely 
associated with the development of cancer.  
 
The link between the Mismatch repair pathway and cancer  
Mutations in the MMR genes account for the majority of hereditary nonpolyposis 
colon cancer (HNPCC) and also contribute to the development of spontaneous colorectal 
cancers.  HNPCC is an autosomal dominant disorder, generally resulting from the 
inheritance of one mutant allele and somatic mutation of the remaining allele.  Similar to 
FA, MMR deficiency can be multigenic and mutations in 5 of the 6 genes have been 
identified in colon cancer patients 58-62.  Interestingly, patients with mutations in one of 
the MMR genes, PMS2, display phenotypes similar to that of FA patients including café-
 
 21
au-lait skin patches, childhood onset hematological cancers such as leukemia and solid 
brain tumors including, astrocytomas and glioblastomas 63.     
Cells from patients with mutations in the MMR genes demonstrate microsatellite 
or genomic instability.  Microsattelites are short repetitive sequences within the genome 
and are themselves non-threatening, however, during replication they are susceptible to 
slippage errors by the polymerase enzyme 13.  The MMR proteins are critical in the repair 
of these errors and if they are left unrepaired the microsatellite can become shorter or 
longer in length.  Thus, MMR deficient cells are prone to generate microsatellite 
instability.  This phenotype has been instrumental in genetic screens for patients with 
tumors suggestive of HNPCC, as approximately 90% of HNPCC tumors are positive for 
microsatellite instability 64 .   
In addition to surveying DNA for mismatches during replication, the MMR 
pathway recognizes methyl adducts incorporated into DNA by chemical agents such as 
MNU, MNNG, TMZ, and 6TG.  Following cellular exposure to methylating agents the 
replication machinery creates GT mismatches (and other mismatches to a lesser extent) 
and triggers activation of the MMR pathway 65.  Unfortunately for the cell, the O6 MeG is 
repeatedly paired with a T, resulting in a futile cycle of repair, activation of the G2 
checkpoint, and induction of apoptosis.  Therefore, MMR proficient cells are sensitive to 
methylation agents.  However, MMR deficient cells have been characterized by their 
unique resistance to methylating agents and researchers have hypothesized that this 
resistance may be attributed to defects in damage recognition, G2 arrest, and/or induction 
of apoptosis 66.  
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MMR pathway activation  
The MMR pathway can be divided into 4 steps, recognition, recruitment, 
excision, and resynthesis and is composed of the MSH2, MSH3, MSH6, MLH1, MLH3, 
PMS1 and PMS2 proteins.  Similar to the FA/BRCA pathway, several subcomplexes 
within the human MMR pathway have been identified and include the MSH2/MSH6 
heterodimer (MutSα), MSH2/MSH3 (MutSβ), MLH1/PMS2 (MutLα), MLH1/PMS1 
(MutLβ), and MLH1/MLH3 (MutLγ).  It’s important to note that although two MutS and 
MutL subcomplexes exist approximately 90% of MSH2 exists as MutSα and similarly, 
90% of MLH1 exists as MutLα 65.  It is believed that misincorporation or insertion loops 
arising during DNA replication are recognized and bound by MutSα resulting in 
activation of the MMR pathway.  The MutSα mismatch-containing complex is then 
bound by the MutLα heterodimer together the complex traverses the DNA in an ATP 
dependent manner.  This function may be critical for differentiating between the template 
strand and the nascent strand at the site of a mismatch.  In E. coli the template strand is 
methylated and the MMR machinery exploits this characteristic to differentiate between 
the two strands and remove the incorrect base from the newly synthesized strand.  In 
mammalian cells it is hypothesized that the MutSα/MutLα complex translocates along 
the DNA and the newly synthesized strand is discriminated from the template strand by 
the presence of Okazaki fragments.  Additionally, MutLα has also been shown to both 
displace DNA polymerase and PCNA at sites of DNA synthesis and also recruit the 
exonuclease, EXO1, in the presence of a mismatch.  Recent data supports bi-directional 
activity of EXO1 in either a 5’-3’ or 3’-5’ polarity depending on the location of the 
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mismatch relative to the nick, or potentially, the Okazaki fragment.  EXO1 excises the 
nascent strand of DNA and the single stranded binding protein, RPA, stabilizes the single 
stranded region of the template strand for resynthesis.  Finally, the gap in the nascent 
strand is resynthesized and the mismatch is corrected.  Although, the exact polymerase 
responsible for this resynthesis remains unclear, Pol δ, Pol α, Pol ε, and Pol η have all 
been implicated (Figure 1-5) 67.   
In addition to misincorporation during DNA synthesis, several DNA methylators 
including MNU, MMNG, TMZ, and T6G activate the MMR pathway.  In MMR 
proficient cells MNU adducts such as O6 MeG are removed by the MGMT enzyme.  
However, genetic analysis has shown that this gene is silenced by promoter 
hypermethylation in sporadic colon cancers resulting in the persistence of DNA methyl 
adducts 13.  In vitro data has demonstrated that the MutSα complex is capable of both 
binding DNA methyl adducts and triggering the MMR pathway.  Unfortunately, the 
persistence O6 MeG adducts causes constant misincorporation and it is this process, 
repeated excision and inaccurate resynthesis, that results in the futile cycle of repair 
ultimately leading to cell death 13. 
 
MMR proteins and DNA damage repair 
The MMR pathway is responsible for correcting DNA mismatches that arise not only 
during DNA synthesis, but also during genetic recombination.  Specifically, the MMR 
proteins inhibit recombination between divergent sequences in a process called 
homeologous recombination.  During recombination the MMR proteins are presumably 
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activated by the formation of heteroduplex DNA between two homologous DNA strands.  
When this recombination intermediate contains low sequence divergence MMR proteins 
process the base errors as they would if the mismatch were encountered during DNA 
replication.  However, if the heteroduplex DNA contains highly divergent sequences the 
MMR proteins function to disrupt the recombination intermediate inhibiting error-prone 
recombination.  Thus, loss of the MMR pathway causes an increase in homeologous 
recombination and can result in chromosomal rearrangements and/or translocations 
compromising genetic integrity and predisposing cells to tumor formation 66.  Although 
the exact mechanisms for suppressing homeologous recombination are unclear several of 
the human MMR proteins have been implicated in this antirecombination process 
including MSH2, MSH3, and MSH6 68.  In fact, gene targeting experiments demonstrated 
both MSH2 -/- and MSH6 -/- murine embryonic stem cells had a substantial increase in 
recombination between heterologous sequences as compared to the recombination 
frequencies in control cells 69-71.   
 
MMR proteins and checkpoint 
Similar to cells defective for FA proteins, cells deficient in the MLH1 and MSH2 
MMR proteins also show a defect in the intra-S-phase checkpoint as demonstrated by 
RDS experiments.  More specifically, loss of either protein results in both disruption of 
CHK2 mediated DNA damage signaling and degradation of CDC25A following 
treatment with IR.   
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Figure 1-5: Cartoon illustration of the Mismatch Repair Pathway.  Following 
methylation damage and incorporation of a mismatch the MSH6/MSH2 heterodimer 
recognizes the mismatch and recruits the MLH1/PMS2 heterodimer.  This complex then 
recruits the EXO1 exonuclease and the incorrect base is removed and replaced with the 
Watson-Crick base to restore the original sequence. 
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MMR deficient cells do not demonstrate decreased cell survival when exposed to 
IR suggesting that the cell cycle defects may be attributed to defects in signal 
transduction pathways 72. 
Research has also shown that cells defective for the MMR proteins fail to activate 
the G2 cell cycle checkpoint following exposure to methylating agents 73,74.  This 
checkpoint is only activated following the second progression through S-phase, further 
supporting the hypothesis that checkpoint activation appears to require signaling and/or 
processing of intermediates, not simply damage recognition.  Additionally, activation of 
the G2 checkpoint requires MLH1, ATR, and CHK1 proteins.  Although controversial, it 
has been speculated that inactivation of the G2 checkpoint in MMR deficient cells may 
actually contribute to the methylation resistant phenotype these cells display 75. 
 
CONCLUDING REMARKS 
It is clear that the DNA damage response is a complex network of pathways 
coordinating the reversal and/or removal of DNA damage to maintain genomic stability 
and ultimately, suppress cancer development.  Our efforts were initially focused on 
deciphering the specific role of the FANCJ helicase in the DNA damage response 
pathway.  However, subsequent findings uncovered a novel connection between the 
FA/BRCA and MMR pathways.  Although it was known that both FA/BRCA and MMR 
pathways were crucial components of the DNA damage response, the relationship 
between the two pathways had been previously undiscovered.  Thus, it became our goal 
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to understand whether FA/BRCA and MMR pathways were coordinated in their DNA 
damage repair and genomic maintenance functions. 
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CHAPTER II 
 
BACH1 is a DNA repair protein supporting BRCA1 damage response 
 
Abstract 
  
The link between defects in BRCA1 and breast cancer development may be best 
understood by deciphering the role of associated proteins.  BACH1 interacts directly with 
the BRCA1 C-terminal BRCT repeats, which are important for BRCA1 DNA repair and 
are mutated in the majority of BRCA1 familial cancers.  Thus, BACH1 is a likely 
candidate for mediating BRCA1 DNA repair and tumor suppression functions. Although 
previous evidence using overexpression of a dominant negative BACH1 has suggested 
that BACH1 is involved in BRCA1-DNA repair function, our results using BACH1 
deficient cells provide direct evidence for involvement of BACH1 in DNA repair as well 
as for localizing BRCA1. Following DNA damage BACH1 is modified by 
phosphorylation, displays a BRCA1-like nuclear foci pattern and co-localizes with 
γ−Η2ΑX. Given that the BACH1/BRCA1 complex is unaltered by DNA damage and the 
intensity of BRCA1 foci is diminished in BACH1 deficient cells, BACH1 may serve to 
not only facilitate DNA repair, but also maintain BRCA1 in DNA damage foci.  
 
Peng*, M., R., Litman*, Z. Jin, G. Fong and S.B. Cantor. BACH1 is a DNA repair 
protein supporting BRCA1 damage response. Oncogene (2006) 25, 2245–2253.  
*Co-First Authors 
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Introduction 
The breast cancer susceptibility gene, BRCA1, is a nuclear phosphoprotein with 
an N-terminus that contains a zinc finger RING domain, and a C-terminus that contains 
two BRCT (BRCA1 C-Terminal) repeats.  BRCA1 has many protein partners and 
numerous ascribed functions including ubiquitin ligase activity, 76,77 transcriptional 
activity, 20,78-80 DNA repair, cell cycle control, and chromatin remodeling functions 81.  
However, it is not certain which protein partners contribute to BRCA1 function(s) and it 
is not clear which BRCA1 function(s) contribute to BRCA1 tumor suppression.  
  BRCA1 is phosphorylated after genotoxic stress in a manner dependent upon the 
DNA damage signaling proteins ATM, ATR, Chk1, and Chk2 82-85. During S-phase or 
after treatment with DNA damaging agents, BRCA1 is in nuclear foci with several other 
DNA repair proteins including BRCA2, Rad51, and NBS1/Mre11/Rad50 complex 36,86-88. 
Recruitment and localization of BRCA1 in these foci is dependent on phosphorylation of 
the histone variant, H2AX-phosphate (γ−Η2ΑX) 87 and the MDC1 protein 89. In the 
absence of functional BRCA1 cells exhibit spontaneous and induced chromosomal 
aberrations, are sensitive to DNA damaging agents, and demonstrate loss of cell cycle 
checkpoints 20. Interestingly, BRCA1 mutations that affect the ability of BRCA1 to 
localize in nuclear foci also affect the ability of BRCA1 to mediate an effective DNA 
damage response 90 suggesting that BRCA1 foci formation is critical for BRCA1 
function.  
Evidence suggests that the C-terminus of BRCA1, including the BRCT domains, 
is important for BRCA1 focus formation 90,91. The integrity of the BRCA1 BRCT 
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domains has also been shown to be critical for both BRCA1 DSBR function and HR 
21,37,92,93.  Moreover, nearly all BRCA1 germline mutations involve either truncation or 
loss of the C-terminal BRCT domains 94. These data suggest that BRCA1 DNA repair 
and tumor suppression functions are linked and highlight the importance of the BRCT 
domain.  
Proteins that bind the BRCT domains may participate in some or all of these 
BRCA1 BRCT domain specific activities including BRCA1 focus formation, DSBR, HR, 
and tumor suppression.  In particular, a candidate mediator of BRCA1 function is 
BACH1, which was identified by its direct binding to the BRCT domains 5.  This binding 
was shown to be dependent on BACH1 phosphorylation at serine 990 and critical for 
BRCA1 to mediate the G2/M checkpoint 95,96. BACH1 makes physical contacts with 
residues located at the interface of the both BRCTs 90,97,98, substantiating the finding that 
multiple clinical BRCT mutations disrupt BRCA1 binding to BACH1.  
We hypothesized that BACH1 is critical to mediate BRCA1 DNA damage 
response given its direct binding to BRCA1 and its helicase function. In fact, 
overexpression of a BACH1 helicase mutant disrupted the kinetics of DSBR in a BRCA1 
binding dependent manner 5.  In addition, BACH1 helicase activity may also contribute 
to BRCA1 tumor suppression function given the identification of hereditary breast cancer 
patients with helicase disrupting mutations in BACH1 6. In this report, we provide 
evidence that BACH1 not only participates in the DNA damage response, but also 
supports BRCA1 localization in DNA damage foci.   
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Results 
Resolution of DSB is delayed in BACH1 deficient cells 
 To directly test whether BACH1 function is required for efficient repair, we 
evaluated the ability of BACH1 deficient cells to repair IR induced DNA breaks. We 
suppressed BACH1 protein expression with an shRNA vector targeting BACH199.  
Infection of MCF7 or SKOV3 cells with either vector led to substantial suppression of 
BACH1 expression (Fig. 2-1a and b).  However, shRNA directed against enhanced green 
fluorescent protein (eGFP) target sequence had no effect on the level of BACH1 protein 
expression (Fig. 2-1a and b).  Moreover, the suppression of BACH1 expression with the 
shRNA vectors is stable for as many as four months in culture with no detectable 
alterations in BRCA1 levels or in levels of β-actin (Fig. 2-1a).  IR induced DSBs can be 
visualized by scoring phosphorylation with an antibody (Ab) specific to the variant 
histone H2AX at serine 139 (γ -H2AX) 14.  Phosphorylation of γ−Η2ΑX occurs rapidly 
after DSBs occur 100 and resolution of DSBs results in loss of γ−Η2ΑX phosphorylation 
similar to the timing of resolution of DSBs imaged by pulse field gel electrophoresis 101.  
Here, we use γ−Η2ΑX foci to detect the presence of IR-induced DSBs. MCF7 cells were 
plated, either left untreated or treated with IR, collected at different time points  
post-IR, and prepared for immunofluorescencesence (IF) using a γ−Η2ΑX Ab (Upstate). 
We quantified the kinetics of repair by scoring the percent of cells containing damage 
induced γ−Η2ΑX foci over total DAPI positive cells at several time points after a 
sublethal dose of IR, .5 Gray (Gy). γ−Η2ΑX irradiation-induced foci (IRIF) were 
detected initially 30 minutes (min) and 1 hour (hr) post IR at similar levels in both cells 
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stably expressing shRNA for BACH1 or eGFP control, suggesting that the accumulation 
of γ−Η2ΑX at the sites of DNA breaks was not affected by BACH1 deficiency (Fig. 2-
2a).  However, BACH1 deficient cells maintained enhanced IR-induced foci at 4hrs, 6hrs 
and 8hrs (Fig. 2-2b) compared to control cells.  In the BACH1 deficient cells, γ−Η2ΑX 
foci were not only found in more cells but these foci were brighter and larger (Fig 2-2a). 
This enhanced γ−Η2ΑX staining was reverted back to untreated cells 10-24 hrs post IR. 
These results suggest that there is a delay in the resolution of DSBs generated by IR in 
cells deficient in BACH1 protein expression, but that breaks are eventually repaired.  
Consistent with a delay in DSBR, the BACH1 deficient cells demonstrated mild radiation 
sensitivity upon treatment with IR in a four-day survival assay (Fig. 2-2c). Suppression of 
BACH1 with RNAi reagents in SKOV3 and 293T led to similar IR sensitivity compared 
to their respective control cells containing luciferase RNAi (data not shown).  
   
BACH1 is phosphorylated after DNA damage and remains bound to BRCA1 
The delay in DSBR detected in the BACH1 deficient cells is consistent with 
BACH1 functioning in a DNA damage repair. In order to further evaluate BACH1’s role 
in DNA repair, we began by addressing whether BACH1 protein responded to DNA 
damage.  First, we examined whether BACH1 demonstrated a post-DNA damage 
response similar to BRCA1 82,83,102. We hypothesized that if BACH1 was active in DNA 
repair similar to BRCA1, it would respond to DNA damage. We found that multiple 
forms of genotoxic stress previously shown to lead to BRCA1 induced phosphorylation 81 
resulted in the slower migration of BACH1 (Fig. 2-3a). The change in BACH1 migration 
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returned to its normal pre-damage migration as detected by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) after treatment with serine/threonine 
phosphatases (λPpase) suggesting that the observed modification was a result of 
phosphorylation.  The reversal in gel migration as a result of λPpase treatment occurred 
irrespective of the type of DNA damage (Fig. 2-3b). Moreover, inclusion of phosphatase 
inhibitors (λPpase inhib.) with the serine/threonine phosphatases prevented the return of 
BACH1 to its normal pre-damage migration further supporting the finding that DNA 
damage induced change in BACH1 migration was due to phosphorylation (Fig. 2-3b).  
The DNA damage induced phosphorylation appears to be both dose and time dependent.  
Maximum gel retardation is obtained by treating cells with 50 J/m2 of ultraviolet light 
(UV), 1mM hydroxyurea (HU), or 20 Gy of IR, whereas 12 Gy of IR generates 
intermediate BACH1 migration that reaches maximal at 8 hrs post-IR (Fig. 2-3c). The 
post-DNA damage BACH1 gel retardation was present in multiple cell lines including 
HeLa, SKOV3, and 293T as well as in cells that lack functional BRCA1 (HCC1937 cells) 
(data not shown) indicating that this is not a cell specific event and that BRCA1 is not 
required for BACH1 post-damage processing.  We next addressed whether DNA damage 
changed the equilibrium of the BRCA1-BACH1 complex. Immunoprecipitation (IP) 
experiments followed by Western blot analysis demonstrated that co-precipitating 
BACH1/BRCA1 proteins were not noticeably changed by DNA damage (Fig. 2-3c). 
Quantification of the percent BRCA1 in a BACH1 IP showed that the percentage of 
BRCA1-bound BACH1 was unchanged at 15 min to 8 hrs post-IR (Fig. 2-3c) suggesting 
that neither DNA damage nor the DNA damage-induced phosphorylation of BRCA1 or 
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BACH1 affected the complex.  Consistent with this finding, phosphorylation of BACH1 
at S990, the site critical for BRCA1 binding, is not changed after DNA damage (data not 
shown).  Moreover, co-localizing BRCA1 and BACH1 nuclear foci are easily detected 
before and after IR (Fig. 2-3d).  
 
BACH1 and γ−Η2ΑX foci co-localize after DNA damage  
To better assess the role of BACH1 in the DNA repair response, we addressed if 
and when BACH1 localized to sites of DNA damage by testing whether BACH1 IRIF co-
localize with sites of DSBs as has been shown for BRCA1 87. MCF7 cells irradiated with 
12Gy IR demonstrated BACH1 IRIF pattern that overlapped with the γ-H2AX IRIF 
pattern. Irradiation-induced co-localization of BACH1 and γ−Η2ΑX was detectable from 
5min to 24hrs post-IR (Fig. 2-4). These results suggest that BACH1 response to IR is 
similar to the published BRCA1 response 87 in that BACH1 and BRCA1 IRIF diffuse and 
reform with similar kinetics and both proteins form early and late IRIF co-staining with 
γ−Η2ΑX.  In addition, the pattern of BACH1 and BRCA1 foci was similar after DNA 
damage (Table 2-1).  As reported previously, we found that the BRCA1 IRIF were 
disrupted within 1 hr and then gradually reassembled into bright foci 103.  By 6 to 8 hrs 
after IR 70% to 90% of nuclei were positive for BRCA1 IRIF and remained until 12 hrs 
88. BACH1 foci pattern resembles the BRCA1 foci pattern overall. In untreated cells 
BACH1 and BRCA1 foci are 35.9% and 36.5% respectively and BACH1 and BRCA1 
IRIF reach maximum 6 hrs post-IR at 78.9% and 75.3% respectively (Table 2-1).  
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BACH1 deficient cells demonstrate reduced BRCA1 foci 
 Since loss of BACH1, leads to enhanced cellular sensitivity to DNA damage and 
defects in DSBR kinetics, two consequences of BRCA1 deficiency, we reasoned that this 
result could be due to loss of BRCA1 at sites of DNA damage. In fact, BACH1 has been 
proposed to localize BRCA1 into nuclear foci given the finding that BRCT mutations in 
BRCA1 disrupt both BACH1 binding and BRCA1 nuclear foci formation 90,98. These 
results are complicated by the fact that these BRCT mutations may also disrupt the 
binding of other BRCT interacting proteins like CTIP or RNA helicase A 104, making it 
unclear whether BACH1 is truly directing BRCA1 to foci or whether other BRCT 
interacting proteins are directing BRCA1 to foci.  
To directly examine the contribution of BACH1 to BRCA1 localization, we 
analyzed BRCA1 foci formation in BACH1 deficient cells. BRCA1 foci were present, 
but appeared less intense overall in BACH1 deficient cells compared to control cells 
while γ−Η2ΑX signal was unaltered (Fig. 2-5a). Nevertheless, these BRCA1 foci present 
in the BACH1 deficient cells colocalized with γ−Η2ΑX IRIF (Fig.2-5a).  The reduced 
BRCA1 foci present in BACH1 shRNA containing cells was not due to a decrease in 
BRCA1 protein levels (Fig. 2-1a ) and BRCA1 post-damage phosphorylation was 
unchanged (Fig. 2-5b).  Thus, we reasoned that the reduced BRCA1 staining was not due 
to changes in BRCA1 expression, we hypothesized that BACH1 deficiency may effect 
the kinetics of BRCA1 localization in IRIF.  Cells expressing shRNA for BACH1 or 
eGFP control (Fig. 2-5c) were not treated or treated with low-dose IR of 2.5Gy, a sub-
lethal dose that generates DNA damage induced BRCA1 and γ−Η2ΑX IRIF immediately 
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post-IR.  Cells were collected at the indicated time-points post-IR and stained with 
BRCA1 and γ−Η2ΑX Abs (Fig. 2-5c). As before, a visible reduction in BRCA1 staining 
was detectable in all BACH1 deficient cells (Fig. 2-5d). In addition, a measurable 
reduction in cells positive for BRCA1 foci (> 10 foci/ cell) was clearly detected from 8-
30 mins post-IR (Fig 2-5c and d). Although complete recovery in BRCA1 foci intensity 
was not achieved in BACH1 deficient cells, the number of cells positive for greater than 
10 BRCA1 foci per cell was similar to control cells by 1hr post-IR (Fig. 2-5d). Together 
these results suggest that BRCA1 foci are dependent on BACH1 at early times post-IR 
for nucleation at sites of DNA damage and for maintenance of BRCA1 foci.  
To confirm our finding that BACH1 deficiency disrupted normal BRCA1 foci 
formation, BRCA1 foci were characterized in the BACH1 deficient cell line, EUFA30-F.  
This cell was derived from an FA patient previously assigned to the FA-J 
complementation group 33.  Recently, several groups have identified the gene defect in 
the FA-J complementation group as BACH1 99,105-107.  The FA-J cells, EUFA30-F, have a 
homozygous point mutation in the BACH1 gene encoding a premature stop codon 
resulting in undetectable BACH1 protein expression.  Re-introduction of WT BACH1 
corrects the post-DNA damage G2/M accumulation in these cells 99.  Here, we have also 
re-introduced FA-J cells with either WT BACH1 or vector alone using lentiviral vectors 
99. Cells stably expressing the vectors were drug selected and analyzed by Western blot to 
confirm BACH1 expression (Fig. 2-6a).  To investigate whether BACH1 is important for 
BRCA1 foci formation in these cells, we analyzed FA-J cells reconstituted with WT 
BACH1 or vector alone for the ability of these cells to form BRCA1 foci. FA-J cells with 
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BACH1 or empty vector were seeded on coverslips, either left untreated or treated with 
2.5Gy IR, and cells positive (> 10 foci/cell) for BRCA1 foci were counted.  The cells 
reconstituted with WT BACH1 had a greater percentage of cells positive for BRCA1 foci 
then the cells reconstituted with empty vector alone, both before and after DNA damage.  
Approximately, 50% of FA-J cells reconstituted with WT BACH1 were positive for 
BRCA1 foci, however, only 25% of the FA-J cells reconstituted with the empty vector 
scored positive for BRCA1 foci (Fig. 2-6b untreated).  Following exposure to IR, both 
WT BACH1 and empty vector FA-J cells contained BRCA1 foci that colocalized with 
γ−Η2ΑX suggesting that BACH1 is not required for BRCA1 colocalization with 
γ−Η2ΑX (Fig. 2-6c ). However, WT BACH1 reconstituted cells maintained more 
detectable BRCA1 foci at all time points tested (Fig. 2-6b and c) up to 24hrs following IR 
treatment (data not shown). Perhaps the FA-J cells, unlike the shRNA BACH1 containing 
cells, have a greater disruption in BRCA1 foci formation due to the total lack of BACH1 
protein in the FA-J cells.  Thus, similar to BACH1 deficient cells established by RNAi 
reagents, BACH1 mutant cells also demonstrate defects in the number and intensity of 
BRCA1 foci.   
 
Discussion 
 In this report we have shown that BACH1 deficient cells are sensitive to DNA 
damage and are delayed in the repair of DSBs.  BRCA1 foci formation is not only 
diminished in BACH1 deficient cells, but also BRCA1 IRIF formation is delayed. 
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BRCA1 eventually localizes with γ−Η2ΑX at sites of breaks suggesting that BACH1 
only contributes to recruitment of BRCA1 in IRIF or serves to maintain BRCA1 in IRIF.  
Our findings demonstrate that BACH1 is a DNA repair protein and suggest that 
BRCA1 and BACH1 functions are linked. The same DNA damage-signaling pathways 
that modify BRCA1 also modify BACH1.  Similar to BRCA1, BACH1 post-DNA 
damage modification is most likely phosphorylation since λPpase treatment of post-DNA 
damage BACH1 IPs led to a reversion of BACH1 post-DNA damage slower gel 
migration to a pre-DNA damage gel migration.  Second, similar to BRCA1, BACH1 IRIF 
form immediately after DNA damage and maximum IRIF is obtained at 6hrs post-IR. 
Third, BACH1 mimics BRCA1 post-damage colocalization with γ−Η2ΑX. Given that 
BACH1 DNA damage response mimics BRCA1 DNA damage response, it is not 
surprising that BACH1 binding to BRCA1 is unaltered by DNA damage.  
While BRCA1 binding to BACH1 may be important for localization of BRCA1 in 
foci, 90,98, BACH1 may only contribute to BRCA1 localization since both N-terminal and 
C-terminal portions of BRCA1 have been shown to be required for BRCA1 localization 
91.  Our results in BACH1 deficient cells suggest that BACH1 contributes to BRCA1 
localization, but is not ultimately required.  We predict that BACH1 serves to maintain 
BRCA1 in IRIF and not directly recruit BRCA1 to IRIF. Unlike MDC1 deficient cells in 
which BRCA1 foci do not form in the absence or presence of DNA damage 89, in 
BACH1 deficient cells BRCA1 foci have reduced intensity, but are present.  Moreover, 
BRCA1 IRIF reform in BACH1 deficient cells by 1hr post-IR.   In contrast to BACH1 
deficient cells in which BRCA1 foci returned by 1hr post-IR, in FA-J cells BRCA1 foci 
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did not fully return even at later times post-IR. This difference may result from residual 
BACH1 expressed in the BACH1 RNAi treated cells compared to the FA-J cells used in 
this study, which have no detectable BACH1 protein 99.  Alternatively, differences in the 
cell type or transformation state of the transformed MCF7 cells compared to 
immortalized FA-J fibroblasts may influence the BRCA1 foci formation. Finally, BRCA1 
appears to be appropriately modified in BACH1 deficient cells following IR unlike in 
MDC1 deficient cells in which BRCA1 post-IR modification is disrupted 89. Perhaps the 
mild radiosensitivity found in BACH1 deficient cells reflects the finding that BACH1 
deficient cells are capable of eventually localizing BRCA1 and repairing breaks. BACH1 
may unwind the DNA in the vicinity of the DNA damage and facilitate access of BRCA1 
to these sites. 
Previous results demonstrated that BACH1 is absent from nuclear foci in cells 
devoid of intact BRCA1 suggesting BRCA1 is upstream of BACH1 in the DNA damage 
response pathway.  In these same cells, BACH1 foci will form when WT full-length 
BRCA1 is reconstituted 5. One explanation for these findings may be that BRCA1 serves 
as a scaffold for which multiple repair proteins are localized and stabilized at the sites of 
breaks. Thus, in the absence of BRCA1, BACH1 and other repair proteins fail to form 
distinct repair foci. BACH1 may in turn stabilize BRCA1 at these sites. BRCA1 is a 
dynamic protein that relocalizes after DNA damage and associates with multiple repair 
proteins in multiple complexes.  In doing so, BRCA1 may cycle between bound and 
unbound sites of DNA damage, replication, or transcription to mediate multiple 
functions.  If BACH1 participates in maintaining BRCA1 at any of these sites, BRCA1 
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focus formation would be reduced overall as we detected. In addition, after low dose IR, 
BRCA1 IRIF would be reduced, but not impaired if BACH1 participates with other repair 
proteins to maintain BRCA1 binding to sites of DNA damage in BACH1 deficient cells.  
The direct and highly specific interaction between BACH1 and BRCA1 suggests 
that they are functionally linked.  Consistent with this idea, our findings show that 
BACH1 resembles BRCA1 post-DNA damage response in its localization pattern, 
immediate presence at sites of DNA damage, and in the DNA-damage induced 
phosphorylation pattern.  Moreover, our findings suggest that BACH1 function is 
required for the timely arrival of BRCA1 into DNA damage foci, radioresistance, and for 
normal kinetics of DSBR.  Recently, we demonstrated that BACH1, similar to BRCA1, is 
required for repair of DSBs by HR, MMC resistance, and for maintenance of 
chromosomal integrity 99.  In addition, BACH1 is the gene defect in the FA-J 
complementation group of the FA disease in which patients are plagued by leukemia and 
sarcomas 108.  This finding clearly demonstrates that BACH1 is a tumor suppressor gene.  
The next critical question is whether the BACH1-BRCA1 interaction is required for these 
mutual repair functions, whether BACH1 connects BRCA1 to the FA pathway, and 
whether ultimately BRCA1 and BACH1 tumor suppression functions are linked. Future 
experiments in which the BACH1-BRCA1 interaction is disrupted directly will clarify 
the importance of this complex formation for DNA repair and tumor suppression.  
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Figure 2-1: BACH1 protein is suppressed.  A) Effects of siRNA on protein expression 
in MCF7 and SKOV3 cells are shown by Western blot, whole cell lysates (wce) (top) and 
BACH1 IPs (bottom). B) MCF7 cells containing shRNA for eGFP or BACH1 were 
stained with BACH1 Abs.   
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Figure 2-2: BACH1 deficient cells are delayed in DSBR and have sensitivity to IR.  
A) MCF7 cells containing shRNA for eGFP or BACH1 were either left untreated or 
treated with IR (0.5 Gy) and were fixed at the indicated time points. Cells were then 
stained with γ−Η2ΑX  Ab. The arrow denotes a single cell positive for γ−Η2ΑX (>10 
foci per cell), which displays the variation in intensity of the γ−Η2ΑX signal.  B) The 
percent of MCF7 cells positive for γ−Η2ΑX foci are indicated for each time point with 
standard deviation based on three independent experiments. Over 500 cells were analyzed 
from each time point. C) MCF7 cells containing shRNA for either eGFP or BACH1 were 
treated with increasing dose of IR.  Cell growth was assessed 4 days later using the 
CellTiter glo viability assay (Promega). Each point represents an average of three data 
points from three independent experiments and a composite graph is shown. 
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Figure 2-3: BACH1 is modified after DNA damage. A) MCF7 cells were either left 
untreated or treated with the indicated type of DNA damage. Protein mobility was 
analyzed by Western blot with BRCA1 or BACH1 specific Abs.  B) MCF7 cells were 
either left untreated or treated with 50 J/m2 UV and subsequently BACH1 IPs were 
treated with λ phosphatase and/or λ phosphatase inhibitors as indicated. (C) For 
quantitative analysis of the BRCA1/BACH1 complex, MCF7 cells were either left 
untreated or treated with 12Gy IR and collected 15min, 4hr, and 8hr post-IR. The 
percentage of BRCA1 bound to BACH1 was quantified using a LAS-3000 image reader 
and Image Gauge software.  D) SKOV3 cells were either left untreated or treated with IR 
(12Gy), fixed 4 hrs later, and stained with anti-BACH1 and anti-BRCA1 Abs as 
indicated. 
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Figure 2-4: BACH1 colocalizes with γ−Η2ΑX after IR.  MCF7 cells were either left 
untreated or treated with IR (12Gy). At the indicated time points, cells were stained with 
anti-BACH1 and γ−Η2ΑX Abs. 
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Table 2-1: Focus formation of BRCA1 and BACH1 after IR.  MCF7 cells were left 
untreated or treated with IR (12Gy), allowed to recover for the indicated time, and stained 
with anti-BRCA1 or anti-BACH1 Abs.  A cell nucleus displaying >10 BRCA1 or 
BACH1 foci was counted as a foci positive cell. At least 500 cells were analyzed for each 
time point, +/- represents the standard deviation from the mean. 
 
Time after 
 IR (hours) BRCA1  BACH1  
0 
1.0 
2 
4 
6 
12 
Foci containing cells(%) 
36.5 +/-   5.6  
17.7 +/-   3.7 
44.7 +/-   5.1 
60.2 +/-   5.4 
75.3 +/-   7.0 
69.0 +/-   6.6 
35.9 +/-   4.9 
24.8 +/-   2.9 
43.2 +/-   6.5 
60.6 +/-   8.6 
78.9 +/-   6.1 
52.0 +/-   6.8 
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Figure 2-5: BRCA1 foci are diminished in BACH1 deficient cells.  A) SKOV3 cells 
containing shRNA for either eGFP or BACH1 were either left untreated or treated with 
IR (2.5Gy), were fixed 4hrs later, and stained with Abs for γ−Η2ΑX and BRCA1.  
BRCA1 foci  colocalize with γ−Η2ΑX foci after DNA damage (merge).  B) MCF7 cells 
containing shRNA for either eGFP or BACH1 were either left untreated or treated with 
IR (10Gy or 20Gy) and collected 1 or 3 hrs later, respectively. C) The percent of SKOV3 
cells positive for BRCA1 foci are indicated for each time point with standard deviation 
based on three independent experiments. A cell nucleus displaying >10 BRCA1 foci was 
counted as a foci-positive cell. Over 500 cells were analyzed from each time point.  
D) Representative cell images from each time point are shown. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 47
Figure 2-6: BRCA1 foci are diminished in BACH1 null cells.  A) FA-J cells containing 
either empty vector or WT BACH1 were stained with BRCA1 Abs for IF or analyzed by 
Western blot using BACH1 and β-actin Abs. B) The percent of FA-J cells positive for 
BRCA1 foci are indicated for each time point with standard deviation based on three 
independent experiments. A cell nucleus displaying >10 BRCA1 foci was counted as a 
foci-positive cell. Over 600 cells were analyzed from each time point. B) Representative 
cell images from the 2hrs post IR time point are shown. 
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Materials and methods 
Cell cultures 
MCF7, SKOV3, and 293TD cell lines were cultured in Dulbecco’s modified Eagle 
medium (DMEM) supplemented with 10% fetal bovine serum (Gibco) and antibiotics.  
FA-J fibroblasts (EUFA30-F) 106 containing either empty pLenti vector or WT BACH1 
pLenti vector 95 were grown in DMEM (Gibco) supplemented with 15% FBS, 7µg /mL 
Blasticidin (Sigma) and antibiotics.    
 
Antibodies 
The monoclonal BACH1 Abs 2C10 and IG5 used for IF or as a monoclonal pool for 
Western blot 5  and polyclonal Ab E67 was used as previously described 6. The 
phospospecific BACH1 serine 990 Ab (pser990) was generously provided by the Chen 
laboratory and was used as previously described 95.  The monoclonal BRCA1 Abs SD118 
and MS110 were used as previously described 103 and the polyclonal BRCA1 Ab was 
purchased from (Stressgen Bioreagents). The mouse monoclonal and polyclonal Anti-
phospho-Histone H2AX (Ser139) Abs were purchased from Upstate.  Rhodamine Red-X 
conjugated AffiniPure Goat anti-rabbit IgG and Fluorescein (FITC)-conjugated 
AffiniPure Goat Anti-mouse IgG were purchased from Code Jackson ImmunoReseach 
Laboratories Inc.. 
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Immunoprecipitations and Western blot assays 
Cells were harvested and lysed in lysis buffer (20mMTris[pH8.0],150mM NaCl, 
1mMEDTA, 0.5%NP-40,1mM phenylmethylsulfonyl fluoride,10µg of leupeptin per ml, 
10µg of aprotinin per ml) for 30 min on ice. The extracts were clarified by centrifugation 
for 10min at 13,200rpm.  The cell lysates were incubated with 3µl E67, 30µl protein A 
beads (Amersham) for 2hr at 4°C and washed three times in IP washing buffer 
(20mMTris[pH8.0], 150mMNaCl, 1mMEDTA, 0.5%NP-40).  IPs were boiled in SDS 
loading buffer and proteins were separated using SDS-PAGE. Proteins were 
electrotransferred to nitrocellulose membranes and Western blot assays were carried out 
with the indicated primary Abs over night at 4°C followed by horseradish peroxidase-
conjugated secondary Abs for 1hr at room temperature.  All blots were detected with 
ECL-plus Western Blotting Detection System (Amersham Biosciences) using Biomax 
MR or XAR film (Kodak). Bradford assays were used to determine protein content (Bio-
Rad).  For the DNA damage treatment experiments cells were treated with IR of 10 Gy, 
20 Gy, 1mM HU, and 50J/M2 UV and then collected 1, 3, 24, and 3 hrs later, 
respectively.  Proteins were separated on 4% tris-glycine gels. λ-phosphatase inhibitors 
included sodium orthovanadate and sodium fluoride (NEB), 
 
Cell survival assays 
MCF7 cells were either untreated or damaged with 5 Gy or 10 Gy IR and plated at low 
density.  A baseline reading was taken at the initial cell plating and total ATP was 
quantified as absorbance units after addition of Cell titer Glo reagent (Promega).  Cells 
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were allowed to grow for 4 days and an endline reading was taken to quantify total 
cellular ATP, which was detected as absorbance units.  Total absorbance units were used 
to assess relative viability.  
 
Immunofluorescencesence 
Cells were grown on coverslips in a 6 well plates. Before immunostaining, cells were 
irradiated or left untreated. At different time points, cells were fixed using 
3%paraformalde/2%sucrose in PBS for 10 min, and permeabilized with 0.5% Triton X-
100.  Cells were then incubated with both primary and secondary Abs in 6 well plates for 
1hr at RT. Cells were washed five times for 5min each in PBS after incubation with both 
primary and secondary Abs. Coverslips were mounted using Vectashield with DAPI and 
sealed with nail polish, then stored in the dark at 4°C. IF was performed by an inverted 
Olympus 1X71 fluorescence microscope.   
 
Retroviral or Lentiviral vectors and infection 
The lentiviral shRNA expression vector FSIPPW, (eGFP) targets the sequence 5'-
AAGAACGGCATCAAGGTGAACTT-3' and was described previously 109.  The 
FSIPPW targets BACH1 sequence 5’-AAAGCUUACCCGUCACAGCUU-3’. The 
FSIPPW vectors were a generous gift of Dr. Andrew Kung. The WT BACH1 pLenti 
vector was a generous gift of Dr. Junjie Chen and Xiaochun Yu.  293TD retroviral 
packaging lines were used to produce all shRNA encoding lentivirus. 293TD cells were 
transfected with 2-4µg of plasmid DNA using FugeneTM (Roche) transfection reagent 48 
 
 51
hrs prior to harvesting retroviral or lentiviral supernatants.  Supernatants containing 
8µg/mL polybrene were added to recipient cell lines. Cells were transduced with 
lentivirus and were selected with either 2µg /mL of puromycin (Sigma) for cells 
containing FSIPPW shRNA vectors  or 7µg /mL Blasticidin for cells containing pLenti 
vectors (Sigma).  
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CHAPTER III 
 
BACH1 is critical for homologous recombination and appears to be the 
Fanconi anemia gene product FANCJ 
 
Abstract 
 
We show in this study that cells deficient of the BRCA1-associated BACH1 
helicase fail to elicit HR after DNA DSBs. BACH1 deficient cells were also sensitive to 
MMC and underwent MMC-induced chromosome instability. Moreover, we identified a 
homozygous nonsense mutation in BACH1 in a FA-J patient-derived cell line and could 
not detect BACH1 protein in this cell line. Expression of wild type BACH1 in this cell 
line reduced the accumulation of cells at G2/M phases following exposure to DNA 
crosslinkers, a characteristic of FA cells. These results support that BACH1 is FANCJ. 
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Significance 
 
A functional link between BRCA1 and FA proteins has been controversial.  The 
putative identification of the BRCA1-associated helicase, BACH1, as FANCJ suggests 
that BACH1 could link BRCA1 to the FA pathway.   In addition to a role for BACH1 in 
breast cancer, we predict a wider role for BACH1 in disease mechanisms, including the 
bone marrow failure and predisposition to leukemia associated with FA.  These results 
suggest that BACH1 may function as a FA gene product by a direct role in HR.  
Determination of the mechanistic relationship of BACH1 to other FA gene products now 
becomes an important topic for future investigation. 
 
Introduction  
DNA repair pathways are critical for the maintenance of genomic stability and 
defects in these processes are frequently associated with cancer.  For example, 
inheritance of germline mutations that affect one allele of either of the breast cancer 
susceptibility genes, BRCA1 or BRCA2, confers susceptibility to breast and ovarian 
cancer. In the absence of functional BRCA proteins, cells are sensitive to DNA damaging 
agents, and exhibit spontaneous and DNA damage-induced chromosomal aberrations 20.  
Additionally, numerous chromosomal fragility disorders are associated with cancer 
susceptibility 104. Among these is FA.  FA is associated with chromosome instability, 
both spontaneously and in response to DNA crosslinkers such as MMC, and also with an 
increased risk of leukemia and other cancers 110. 
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Unlike BRCA1 or BRCA2 associated breast cancer, FA is a multigenic disorder, 
with at least eleven distinct complementation groups 111.  Nine FA genes have been 
cloned, but FANCI and FANCJ, which are associated with the FA-I and FA-J 
complementation groups, respectively, have remained unidentified 33.  The FA proteins 
are organized into a pathway in which a complex that includes seven of the identified FA 
gene products, FANC- A, B, C, E, F, G, and L, are required for the monoubiquitination of 
the FA protein, FANCD2 23.  Monoubiquitination of FANCD2 is required for resistance 
to MMC, maintenance of chromosome stability, and for the assembly of FANCD2 foci, 
which colocalize with proteins such as BRCA1 and Rad51 following exposure to DNA 
damage 23,27,112.  Neither, FANCD1, which is BRCA2 22, nor FANCJ are required for 
FANCD2 monoubiquitination, either with or without exposure to DNA damage 22,32,33.  
Consequently, it has been suggested that BRCA2/FANCD1 and FANCJ function 
downstream in the FA pathway, following activation of FANCD2 by monoubiquitination. 
In addition to the identification of BRCA2 as the FA gene, FANCD1 22, other 
observations suggest a potential relationship between BRCA and FA proteins.  Among 
these, deficiency in either BRCA1 or BRCA2 results in hypersensitivity to MMC, similar 
to that observed in FA cells 22,113-115. Also, BRCA1 is required for FANCD2 foci 
formation 25, and BRCA1 was shown to immunoprecipitate (IP) with FANCD2 in DNA 
damaged cells 23.  Moreover, BRCA1 and BRCA2 colocalize with FANCD2 in DNA 
damage induced foci 23,116.  But, whether BRCA1 is required for DNA damage-induced 
FANCD2 monoubiquitination has been controversial 23,25.  
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Several lines of evidence indicate that the BRCA and FA pathways influence HR-
mediated DNA repair. BRCA1 and BRCA2 deficient cells are defective for DSB induced 
HR (reviewed in 20,81).  Likewise, in chicken DT40 cells, fancc, fancg, and fancd2 
mutants show reduced HR 44,117,118.  DNA damage that activates HR can be measured by 
the induction of Rad51 foci 119.  Deficiency of BRCA1 or BRCA2 attenuates the DNA 
damage-inducible assembly of Rad51 foci 93,120.  It has been proposed that through 
monoubiquitination of FANCD2, FA proteins serve to stabilize broken replication forks 
making Rad51-mediated recombination more efficient 121. While the specific contribution 
of FA proteins to HR is not clear, it appears that FANCD2 monoubiquitination is 
required for efficient HR 35,43,111. 
BACH1, which was identified by its direct binding to the BRCA1 BRCT 
domains, was shown to participate in DNA DSBR with BRCA1 5.  In this report, we have 
generated mammalian cells in which expression of BACH1 has been suppressed to better 
characterize the role of BACH1 in the DNA damage response. We provide direct 
evidence that BACH1 is critical for the repair of DNA DSBs by HR.  BACH1 deficient 
cells are defective for HR, hypersensitive to MMC, and display increased levels of 
MMC-induced chromosomal instability, suggesting a potential relationship to the FA 
pathway. Indeed, we find that a FA-J cell line lacks detectable BACH1 protein and 
maintains a biallelic truncating mutation in BACH1.  Further, we find that FA-J cells, 
like other FA cells display a pronounced G2/M accumulation following exposure to DNA 
interstrand crosslinkers 122-127, and this phenotype is corrected by expression of BACH1.  
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Together these results suggest that BACH1 is the FANCJ gene functioning in HR 
downstream of FANCD2.  
 
Results 
HR is disrupted in BACH1 deficient cells 
BACH1 function in DSBR was identified by the finding that overexpression of a 
helicase dead version of BACH1 delayed DSBR kinetics 5.  To more directly address the 
role of BACH1 in DSBR, we examined the biological consequence of BACH1 deficiency 
on the repair of DSBs by HR. Using a similar assay system in which BRCA1 has been 
shown to support HR 37, we examined the ability of BACH1 deficient cells to support HR 
in response to DSBs.  We established an MCF7 cell line with an integrated copy of the 
pDR-GFP reporter as described previously 128. Puromycin-resistant cell lines were 
isolated and screened for the ability of an I-Sce1 induced DSB to generate HR.  If HR 
occurs, GFP is expressed and GFP positive cells can be quantified by flow cytometry 128.  
Twenty-four hours after transfection with short interfering RNAs (siRNA) targeting 
BACH1 or BRCA1, the MCF7 DR-GFP cells were subsequently transfected with pCMV-
I-Sce1. MCF7 DR-GFP cells transfected with luciferase (luc) siRNA then with pCMV-I-
Sce1 were used as a control. Three days after I-Sce1 transfection, the cells were analyzed 
by flow cytometry to determine the percentage of green fluorescent cells relative to the 
total cell number. Transient transfection of the I-Sce1 endonuclease demonstrated that 
MCF7 DR-GFP cells exhibit I-Sce1 inducible HR, producing GFP positive cells 
quantified by flow cytometry (Figure 3-1A).  The percentage of I-Sce1 induced GFP 
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positive cells was greatly reduced in cells previously transfected with siRNA to BRCA1 
or with either of two different siRNA to BACH1 (A or B) than cells transfected with 
siRNA against luc.  The I-Sce1 induction of GFP positive cells (~ 0.5%) was similar to 
what has been observed previously 113.   In contrast, the I-Sce1 induction in cells with 
BACH1 siRNA led to an average of ~0.048% cells that were positive for GFP, which is, 
~10 fold lower than the GFP positive cells containing the luc control siRNA (average p-
value .00051) (Figure 3-1B).  The number of GFP positive cells were reduced to 0.07%, 
that is ~7-fold lower in cells with siRNA to BRCA1, as compared to luc controls (p-value 
.00029) (Figure 3-1B). The siRNA-mediated suppression of BACH1 and BRCA1 was 
specific to their respective target proteins whereas siRNA directed against luc had no 
effect on the levels of BACH1 or BRCA1 protein (Figure 3-1C).  The overall transfection 
efficiency with pCMV-I-Sce1 was not affected by the siRNA transfection (data not 
shown). These results demonstrate that BRCA1 and BACH1 deficiency lead to a defect 
in DSBR by HR.   
 
BACH1 deficient cells are sensitive to MMC 
 The reduction in HR frequency in BACH1 deficient cells prompted us to test 
whether BACH1 deficient cells were also sensitive to MMC.  MMC induces DNA 
interstrand crosslinks, which are repaired by a mechanism relying in part on HR 121. To 
examine the effects of MMC treatment, we suppressed BACH1 protein expression with 
BACH1 siRNA.  Previous reports have demonstrated that BRCA1 deficient cells are 
sensitive to MMC 113,114.  Thus, we also suppressed BRCA1 protein expression with 
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siRNA to compare the effects of MMC on survival in BACH1 or BRCA1 deficient cells.  
Transfection of MCF7 cells with the BACH1 or BRCA1 siRNA led to substantial 
reduction of BACH1 or BRCA1 protein levels, respectively, as compared to control cells 
transfected with luc siRNA. Transfections with these siRNA did not induce detectable 
alterations of β-actin protein levels (Figure 3-2B). Photometric assays showed that 
BACH1 and BRCA1 deficient cells were extremely sensitive to MMC as compared to 
control cells (Figure 3-2A).  Representative results from one of three independent 
experiments are shown in which the SF50 (dosage at which 50% of cells survived) for 
MMC was ~10-100 nM for BACH1 and BRCA1 -deficient MCF7 cells, as compared to 
1000 nM for MCF7 cells transfected with luc siRNA. Similar MMC sensitivity results 
were obtained with suppression of BACH1 or BRCA1 in HEK cells (data not shown).  
In order to determine whether MMC led to chromosomal abnormalities in 
BACH1 deficient cells, we compared BACH1 deficient and control cells treated with 100 
nM MMC for four days. For these experiments, shRNA lentiviral vectors targeting 
BACH1 (A) or enhanced green fluorescent protein (eGFP), used as a control, were 
designed and used to infect HMEC cells.  BACH1 protein level was efficiently reduced 
in cells expressing BACH1 shRNA (Figure 3-2D).  BACH1 deficiency led to chromatid 
breaks and more complex chromatid aberrations such as triradial and quadriradial 
chromosomes. At the same dose, such aberrations were rarely seen in control eGFP 
shRNA HMEC cells (Figure 3-2C). These findings suggest that BACH1 deficiency leads 
to a failure to repair DSBs by HR.  As suggested previously, other mechanisms to repair 
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DSBs such as single-strand annealing and/or non-homologous end joining most likely fail 
to maintain chromosome integrity 129,130. 
 
DNA damage-induced FANCD2 monoubiquitination and Rad51 foci formation are 
intact in BACH1-deficient cells 
Inactivation of BACH1 yields defects in HR, hypersensitivity to MMC, and 
increased MMC-induced chromosome instability similar to inactivation of FA genes 
35,110,117.  This suggested a possible relationship of BACH1 to the FA pathway, although 
inactivation of genes that have not been identified as FA genes, such as BRCA1 and 
Rad51, also result in similar defects 113,114,131. To pursue the relationship of BACH1 to the 
FA pathway, we investigated whether BACH1 function was required for FANCD2 
monoubiquitination. FANCD2 monoubiquitination, as identified by a HU-induced 
increase in a form of FANCD2 which migrates slower by SDS-PAGE (FANCD2-L), was 
the same in BRCA1 and BACH1 deficient cells as in control cells infected with shRNA 
to eGFP (Figure 3-3A).  Suppression of protein expression by shRNA is shown (Figure 
3-3C).  In contrast, FA-A (PD6914) cells do not support FANCD2 monoubiquitination 
unless reconstituted with the FANCA gene, as previously reported 23,43. FA-D2 cells 
served as a control for lacking FANCD2 protein 23 (Figure 3A).  FANCD2 
monoubiquitination was also intact in Hela cells in which BACH1 was suppressed with 
siRNA (data not shown).  
The formation of Rad51 foci is critical for efficient HR 111.  DNA damage-
induced assembly of Rad51 foci is defective in FANCD1 cells expressing C-terminally 
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truncated BRCA2 32,132 and in BRCA1 deficient cells 93.  Based on the finding that HR 
was defective in BACH1 deficient cells, we hypothesized that similar to BRCA1 
deficient cells, DNA damage induced Rad51 foci would be diminished in BACH1 
deficient cells.  However, in response to HU we found that RAD51 foci were present in 
both BACH1 deficient cells and in control cells (eGFP).  In contrast, Rad51 foci were not 
formed in cells deficient for BRCA1 treated with HU (Figure 3-3B). Similar results were 
obtained in MCF7 BACH1 siRNA cells treated with MMC, as well as in BACH1 
deficient SKOV3 cells treated with HU (Supplemental Figure 3-6).  The fact that Rad51 
foci form in BACH1 deficient cells suggests that BACH1 functions independently of 
BRCA1 and potentially downstream of Rad51 (Figure 3-3B).  In contrast, γ−Η2ΑX foci 
form normally in both BRCA1 and BACH1-deficient cell lines following treatment with 
HU (Figure 3-3B).  This suggests that the DNA damage response is initiated normally in 
the absence of BACH1.  
 
FANCJ cells lack detectable BACH1 protein expression and contain a biallelic 
BACH1 truncating mutation. 
There are two FA complementation groups in which the gene defect is not 
currently known. Given our findings that BACH1 functions in the HR pathway and is 
likely to be downstream of FANCD2, we considered whether BACH1 is the gene 
defective in the FA-J complementation group. To test this possibility, we analyzed cell 
extracts from MCF7, hTERT immortalized normal (PD846F), or FA-J (AG656) 
fibroblasts for BACH1 protein expression. Unlike the MCF7 and normal cells, full-length 
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BACH1 was not detected in FA-J cells (Figure 3-4A).  Moreover, IP 
(Immunoprecipitation) with two different BACH1 antibodies, or pull-down with the 
GST-BRCT fusion protein that binds directly to the serine 990 region of BACH1 95, 
failed to precipitate full-length BACH1 in the FA-J cells (Figure 3-4B). Western blot 
analysis using the I82 Ab, which was a polyclonal antibody generated using the full-
length BACH1 protein, did not reveal any detectable BACH1 species in cell extracts or in 
IP experiments (data not shown).  Consistent with the possibility that BACH1 is the gene 
defective in FA-J cells, FA-J cells maintained Rad51 and γ−Η2ΑX foci after HU 
treatment (Supplemental Figure 3-6) similar to the MCF7 cells in which BACH1 was 
suppressed with shRNA (Figure 3-3B).   
We then investigated whether BACH1 was mutated in the FA-J cells. RNA from 
the FA-J cells was purified and RT-PCR was performed using a series of BACH1 
sequence primer sets (Experimental procedures). The RT-PCR generated the expected 
size products as determined using agarose gel electrophoresis (Figure 3-4C).  These 
products were then purified from the agarose gel and subjected to DNA sequencing 
analysis. A C to T alteration was identified at nucleotide 2392 in exon 17 (Figure 3-4D). 
This alteration changes the codon 798 from CGA encoding for arginine to a stop codon, 
TGA. This BACH1 mutation has not previously been reported. The remainder of the 
sequence was intact and read as a homozygous sequence except at nucleotide 2755, in 
which both a T and a C were detected (Figure 3-4D). This polymorphism at nucleotide 
2755 has previously been reported 5. The point mutation at nucleotide 2392 was 
confirmed by sequencing genomic DNA (Supplemental Figure 3-8). The identification of 
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both a C and a T at nucleotide 2755 indicates that the FA-J cells used in this study 
contain two alleles of BACH1 gene and that both alleles contain a C to T mutation at 
nucleotide 2392. 
 
BACH1 cDNA corrects interstrand crosslink-induced G2/M accumulation in FA-J 
cells.    
Characteristically FA cells show an increased accumulation in G2/M following 
exposure to DNA interstrand crosslinkers 122-127. Consistent with this finding, we found 
that FA-J cells accumulated in G2/M after treatment with the interstrand crosslinker, 
melphalan.  In contrast, this accumulation in G2/M was not detected in the normal cells 
(PD846) (Figure 3-5A). Next, we stably infected FA-J cells with cDNA encoding the 
full-length wild-type BACH1 protein 95 using lentiviral infection (Figure 3-5B).  To test 
the ability of wild-type BACH1 cDNA to correct FA-J G2/M accumulation, we treated 
FA-J + vector or FA-J +BACH1 with melphalan.  The FA-J + vector cells had an 
increase in G2/M content similar to the parental FA-J cells, 46.3% and 45.4 % 
respectively.  Whereas, in FA-J + BACH1 cells G2/M accumulation was decreased to 
28.2% (Figure 3-5A).  The G2/M accumulation generated in FA-J cells with MMC was 
also corrected with BACH1 cDNA (data not shown). A comparable correction of the 
accumulation of FA-C cells in G2/M was obtained by reintroduction of FANCC cDNA 
124 and recently this correction of melphalan induced G/M accumulation was 
demonstrated by reconstitution of FA cells with their respective FA cDNAs 127. Taken 
together, these results indicated that BACH1 is the FANCJ gene. 
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Discussion 
In this study, we have characterized the role of BACH1 in HR mediated DSBR 
using mammalian cells deficient for BACH1. BACH1 was first identified by its 
interaction with the BRCT domain of BRCA1 5. Consistent with the possibility that the 
interaction of BACH1 and BRCA1 is of functional significance, we find that HR repair 
stimulated by DSBs is compromised in both BACH1 deficient cells and BRCA1 deficient 
cells.  Further supporting a role for BACH1 in HR-dependent repair, BACH1 deficient 
cells, like BRCA1 deficient and FA cells are extremely sensitive to MMC 22,113-115. 
BACH1 deficiency also results in increased MMC induced chromosome damage, 
suggesting a possible relationship to the FA pathway. Analysis of human FA patient 
derived cells and deletion of various FA genes in chicken DT40 cells has led to the 
conclusion that FA genes also function in HR 35,44,117,118,133.   
FANCD2 monoubiquitination, the central feature of the FA pathway 23,28, is 
unaffected in BACH1 deficient cells.  This is of interest since there are two FA 
complementation groups in which FANCD2 monoubiquitination, either spontaneously or 
in response to DNA damage, is not compromised.  One of these groups is 
BRCA2/FANCD1 22,24.  BRCA2 has an important function in HR, and appears to 
regulate the assembly of the Rad51 filament involved in strand invasion 134,135.  The other 
FA complementation group in which FANCD2 monoubiquitination is normal is FA-J 33, 
for which the defective gene, FANCJ, had not been previously identified.  Our results 
suggest that BACH1 is FANCJ, since BACH1 protein is not detectable in FA-J cell 
lysates, a homozygous BACH1 truncating mutation was identified in FA-J cells, and 
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expression of wild-type BACH1 corrects the drug induced G2/M accumulation found in 
FA-J cells.  These results suggest that BACH1/FANCJ and BRCA2/FANCD1 have 
critical functions in HR downstream of FANCD2 monoubiquitination.  
Since FANCD2 monoubiquitination is normal in FA-J cells 33, it would appear 
that BACH1/FANCJ functions independently of the seven identified FA proteins that are 
present in the FA nuclear complex required for FANCD2 monoubiquitination 23,24,136 and 
downstream of monoubiquitinated FANCD2, like BRCA2/FANCD1.  Potentially 
consistent with this possibility, we find that BACH1 and FANCD2 show partial 
colocalization after treatment with MMC (data not shown).  However, we also find that 
BACH1 and FANCD2 do not co-immunoprecipitate before or after DNA damage (data 
not shown).  Understanding the functional relationship of BACH1/FANCJ to other FA 
proteins will be an important focus of future work. 
Our inability to detect a truncated BACH1 protein by Western blot analysis, 
suggests this truncated BACH1 species is not stably expressed in the FA-J cells.  
Mutations of FANCA predicted to yield premature truncation and an absence of FANCA 
protein are frequently found in human FA-A patients 137,138. Alternatively, the Ab reagent 
used to detect BACH1 may lack the appropriate epitopes to efficiently bind the truncated 
BACH1 species. 
Interestingly, BACH1 and BRCA1 function are distinct with respect to their 
relationship to Rad51 foci. In BRCA1 deficient cells, as previously reported 93, we found 
that Rad51 foci are greatly diminished, placing BRCA1 upstream of Rad51 in the HR 
pathway. In contrast, we found that DNA damage induced Rad51 foci formation was 
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maintained in BACH1 deficient cells. Similarly, fancd2 mutant DT40 cells are deficient 
for DSB-initiated HR but Rad51 foci formation were shown to be intact after MMC 
treatment 118.  Still, it is possible that the assembly of RAD51 foci may merely be delayed 
in BACH1 deficient cells, so examination of the kinetics of the assembly of RAD51 foci 
in these cells will be necessary to completely exclude the possibility that BACH1 may 
regulate RAD51 assembly.  
Our results suggest that there is no correlation between the capacity for I-Sce1 
induced HR and Rad51 foci formation.  This is also supported by results obtained by 
deletion of fancd2 in DT40 cells 133.  We conclude that unlike BRCA1, BACH1 is 
dispensable for the assembly of Rad51 foci in response to DNA damage.  Importantly, 
the DNA damage-induced assembly of Rad51 foci is greatly diminished in FA-D1 cells 
expressing C-terminally truncated BRCA2/FANCD1 24,132.  Because Rad51 foci 
formation is normal in an FA-J cell line (Supplemental Figure 3-6), and in cells in which 
BACH1 has been suppressed (Figure 3-3), BRCA2/FANCD1 and BACH1/FANCJ likely 
have distinct functions in the FA pathway.  
During genetic recombination and the recombinational repair of chromosome 
breaks, DNA molecules become linked at points of strand exchange. Branch migration 
and resolution of these crossovers, or Holliday junctions (HJs), completes the 
recombination process. While BACH1 demonstrates no ability to unwind HJ substrates in 
vitro 6,139 like BLM or WRN helicases 140, BACH1 binds HJ substrates (Cantor 
unpublished).  Given that BLM is a suppressor of HR 141,142, one possibility is that 
BACH1 could promote HR by blocking the access of BLM to the HJ and prevent BLM 
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from unwinding the HJ substrate.  Alternatively, BACH1 could promote branch 
migration similar the E.coli RuvA protein.  After strand invasion and the formation of the 
HJ, RuvA (a HJ specific DNA binding protein) recruits RuvB, which promotes branch 
migration.  Similar to RuvA, BACH1 could serve as a scaffold for assembly of other 
proteins and/or promote branch migration of the HJ.   
Alternatively, BACH1 could participate in processes that affect the dynamics of 
Rad51 filament extension and disassembly like the Srs2 helicase in yeast.  Mutants of the 
Srs2 helicase display enhanced Rad51 foci, as the Srs2 helicase prevents recombination 
by disrupting Rad51 nucleoprotein filaments on single stranded DNA 143.  We have 
shown that BACH1 deficiency disrupts HR without disrupting the assembly of DNA 
damage-induced Rad51 foci.  Thus, BACH1 could function in HR by disrupting Rad51 
nucleoprotein filaments and promote HR by enabling recycling of Rad51 for subsequent 
rounds of HR.  If so, in BACH1 deficient cells, Rad51 could be locked on DNA. Given 
that BACH1 unwinds in a 5’-3’ direction, relative to the DNA to which it is bound 6,139, 
and Rad51 filaments extend in a 5’-3’ direction relative to the single stranded gap, 
BACH1 unwinding could directly serve to strip Rad51 protein filaments upon completion 
of HR.  
The development of gross chromosomal abnormalities in MMC treated BACH1 
deficient cells supports the role of BACH1 in maintaining chromosome stability.  The 
sensitivity of BACH1 deficient cells to MMC is most likely due to an overload of DNA 
damage that forces cells to rely on the error-free HR pathway 144.  In the absence of 
functional BACH1, HR is defective, thus these crosslinked replication forks may persist 
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and be lethal.  Deficiencies for other proteins involved in HR, including BRCA1, 
BRCA2, and Rad51, all result in hypersensitivity to MMC 87,113,114. The repair of DNA 
ICLs, which are induced by MMC, is a multi-step process 44.  Translesion synthesis 
(TLS) and HR appear to cooperate in repair of crosslinks 145, and one way in which HR 
may be involved is in restarting the replication fork following resolution of the damage 
44.  It has been reported that FANCC is epistatic with TLS in chicken DT40 cells 44.  This 
would suggest that the upstream FA pathway, culminating in FANCD2 
monoubiquitination, might have only a modest role in HR 35 and with a greater role in 
TLS.  In contrast, the downstream FA pathway functioning after FANCD2 
monoubiquitination may be directly involved in HR.  This is best supported by the direct 
role of BRCA2/FANCD1 in HR.  Our paper’s findings now place BACH1, which 
appears to be FANCJ directly in the HR pathway as well.  At present, it is unknown 
whether the upstream pathway leading to FANCD2 monoubiquitination simply regulates 
the involvement of the downstream FA proteins in HR, or whether it has a distinct 
function that precedes HR.  
Transient or prolonged suppression of BACH1 in multiple tissue culture cells 
including human mammary epithelial cells, in most cases, led to increased or unchanged 
cell numbers compared to BRCA1 siRNA or siRNA controls (Cantor unpublished). The 
ability of cells to tolerate prolonged BACH1 deficiency in tissue culture cells suggests 
that BACH1 function is not required for proliferation or viability.  Since the extreme HR 
defect in BACH1 deficient cells does not affect cell viability, the cells must be able to 
process DSBs by alternative pathways.  
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The identification of BACH1 mutations in breast cancer patients 5 highlighted the 
possibility that BACH1 is a tumor suppressor.  The finding that BACH1 likely is the gene 
defect in FA-J patients not only links BACH1 to the FA pathway, but also indicates that 
BACH1 function is critical for normal human development as well as for disease 
prevention.  Patients in the FA-J complementation group have several symptoms 
including cafe-au-lait spots, thumb abnormalities, abnormal kidney, microphthalmia 
microcephaly, growth delay and aplastic anemia, which are typical of other FA 
complementation groups 33.  Since such patients typically die at an early age, it is 
unknown whether breast cancer would have developed.  
Our findings suggest that BACH1 function is intimately linked to maintenance of 
chromosome stability and HR. The HR DNA repair defect reported here and previously 
reported checkpoint defects 95 found in BACH1 deficient cells could set the stage for 
genomic instability and eventual transformation. Therefore, we predict that BACH1 will 
be targeted in multiple cancer syndromes in addition to breast cancer. This prediction was 
bore out by the connection of BACH1 to FA, an autosomal recessive disorder that 
encompasses a range of cancer syndromes including leukemia, sarcoma and 
medulloblastoma 146. Interestingly, while kindred heterozygous for BRCA2 mutations are 
predisposed to breast cancer, FA-D1 patients with biallelic mutations of BRCA2 develop 
early onset leukemia 116.  Given the prior association of BACH1 mutations with breast 
cancer 5 this suggests the possibility that FA-J patients with biallelic mutations of 
BACH1 will similarly have a different tumor spectrum than the heterozygous carriers.  
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Future experiments using mouse models or human cancer molecular genetics will ideally 
reveal the true role of BACH1 in tumor suppression. 
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Figure 3-1:  BACH1 deficient cells have a defect in DSB induced HR.  Gene 
conversion of the pDR-GFP construct by HR is observed as GFP positive cells.  The 
percentage of cells with I-SceI induced HR events was quantitated by flow cytometry in 
MCF7 DR-GFP cells, also transiently transfected with either BACH1 (reagent A or 
reagent B), BRCA1, or luciferase siRNA.  A) Representative flow cytometric profiles of 
viable MCF7 DR-GFP cells transfected with the indicated siRNA reagents.  B) Percent 
GFP positive cells are indicated for each siRNA reagent, with standard deviation based 
on three independent experiments.  P-values calculated using the Student’s t-test (P = 
.00051 and .00029 for BACH1 and BRCA1, respectively).  A total of 250,000 events 
were analyzed for each experiment, and experiments were performed in triplicate.  C) 
Western blot of whole cell extracts were prepared from MCF7 DR-GFP treated with 
indicated siRNA using indicated antibodies.  
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Figure 3-2:  BACH1 deficient cells are sensitive to MMC.  A) MCF7 cells transfected 
with luciferase siRNA (diamonds), BRCA1 siRNA (squares), or BACH1 siRNA 
(triangles) were treated with increasing concentrations of MMC.  Cell growth was 
measured by ATP content after 4-5 days of MMC exposure. Experiments were performed 
in triplicate and a representative experiment is shown.B) Effects of siRNA on protein 
expression in MCF7 cells are shown by Western blot. C)  HMEC cells containing shRNA 
to either eGFP or BACH1 were untreated (left) or treated (right) with 100 nM of MMC 
and genetic instability was analyzed by chromosome spreads.  Representative defects 
from various BACH1 deficient cells treated with MMC are shown on far right, a, 
chromosome break, b, quadriradial, and c, triradial. Arrow shows a radial chromosome. 
D) Effects of shRNA on BACH1 protein expression in HMEC cells are shown by 
Western blot 
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Figure 3-3: BACH1 is dispensable for FANCD2 monoubiquitination and Rad51 foci 
formation after DNA damage. A) FANCD2 protein in whole cell lysates from untreated 
or HU-treated (24 hours) MCF7 cells transduced with lentivirus expressing indicated 
shRNA was detected by Western blot. FA-A (a FANCA mutant cell line PD6914) and 
FA-A+FANCA cells (PD6914 expressing wild type FANCA) were used as negative and 
positive controls for monoubiquitination of FANCD2.  FA-D2 (a FANCD2 mutant cell 
line PD20) served as a negative control for the FANCD2 Western blot.  FANCD2-L and 
FANCD2-S represent monoubiquitinated and non-ubiquitinated FANCD2, respectively.  
Asterisk (*) denotes a non-specific band present in all cell lines analyzed, including PD20 
cells lacking FANCD2.  C) MCF7 cells containing shRNA for eGFP, BRCA1, or 
BACH1 were treated with 1 mM HU for 18 hours and stained with either γ−Η2ΑX or 
Rad51 antibody as indicated, or with 4',6-diamidino-2-phenylindole (DAPI),  C) Western 
blot analysis of BACH1, BRCA1, and β-actin in whole cell lysates from MCF7 cells 
expressing indicated shRNA 
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Figure 3-4:  BACH1 protein expression is absent from a patient-derived FA-J cell 
line. A) Whole cell lysates from MCF7, PD846F (normal), and AG656 (FA-J) cells were 
probed with BACH1 and β-actin Abs. B) BACH1 in cell lysates prepared from PD846F 
and AG656 cells was immunoprecipitated using I82 (lanes 1 and 3) or E67 antibody 
(lanes 2 and 4), or was precipitated using GST-BRCT (lanes 5 and 6) and was then 
detected by Western blot using the BACH1 antibody E87. C) A schematic representation 
of the BACH1 coding region shows the PCR products created by the specified primer 
sets (top).   Roman numerals show the relative location of the conserved helicase motifs 
in the helicase domain (dark blue).  RT-PCR was preformed on FA-J cells using 
overlapping primers sets and cDNA products were analyzed by gel electrophoresis 
(bottom).  D) Mutations in the BACH1 gene in the FA-J cell line AG656 were confirmed 
by direct DNA sequencing. The chromatograms shown indicate a C-T point mutation at 
nt2392 (above), and a polymorphism at nt2757 (below).  Together, this indicates a 
biallelic mutation of BACH1 at nt2392 in this human FA-J cell line. 
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Figure 3-5:  Restoration of BACH1 cDNA corrects the melphalan induced G2/M 
accumulation of FA-J cells.  A) PD846F (normal), FA-J, FA-J + vector, and FA-J + WT 
BACH1 cells were either mock treated or treated with 0.5μg/mL melphalan for 65 hr.  
Cells were then collected, stained with propidium iodide, and analyzed by flow cytometry 
to assess DNA content.  Three independent experiments were performed and a 
representative experiment is shown. B) Western blots confirm BACH1 expression in FAJ 
cells infected with lentivirus expressing WT BACH1. 
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Supplemental Figure 3-6: RAD51 foci formation is intact in FA-J cells. A) Normal and 
FA-J cells were treated with 1mM HU for 18 hours and stained using polyclonal Rad51 
and monoclonal γ-H2AX Abs.  B) SKOV3 cells containing shRNA to eGFP or BACH1 
were treated with HU for 18 hours and stained as in A.  C) Effects of shRNA on BACH1 
expression in SKOV3 cells are shown by Western blot. 
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Supplemental Figure 3-7: Relative location of BACH1 protein, or fragments, used to 
make BACH1 antibodies. 
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Supplemental Figure 3-8: Sequencing of FA-J genomic DNA. The mutation in the 
BACH1 gene in the FA-J cell line AG656 was verified by sequencing a PCR product 
generated from genomic DNA from these cells.  The chromatogram shows a C-T point 
mutation at nt 2392 and the respective encoded protein sequence with stop codon. 
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Materials and Methods: 
Homologous Recombination Assay and DNA constructs  
The plasmid, pDR-GFP, utilizes two modified GFP genes to create a 
recombination reporter.  The I-Sce1-GFP gene is a GFP gene that is mutated by an 11 bp 
substitution to contain the 18 bp recognition sequence for the I-Sce1 endonuclease.  
Downstream of I-Sce1-GFP is the 0.8-kb GFP fragment iGFP, which is a wild type GFP 
gene truncated at both its 5’ and 3’ ends.  Expression of I-Sce1 in cells that contain the 
pDR-GFP substrate integrated into their genome results in a DSB in the chromosome at 
the position of the I-Sce1 site.  Repair of the induced DSB in I-Sce1-GFP by a non-
crossover gene conversion with iGFP reconstitutes a functional GFP gene, expression of 
which can be scored by cellular fluorescence.  Although other DSB repair events at the I-
Sce1 site are possible, they are not detected, because the 11bp substitutions in the I-Sce1-
GFP gene cannot be restored to the wild-type GFP sequence except through a templated 
gene conversion event.  Molecular analysis of the pDR-GFP substrate in sorted GFP-
positive cells after I-Sce1 expression has verified that cellular green fluorescence, as 
measured by flow cytometry, results from repair by gene conversion 128. MCF7 DR-GFP 
cells were generated by transfecting ~1X106 MCF7 cells in p100mm dish with 4μg DNA 
plasmid (pDR-GFP) with lipofectamine and Plus reagents (Invitrogen) following the 
manufacturers guidelines. After 24-hours cells were split into fresh dishes at different cell 
densities.  After 48-hour fresh media containing 1.0μg/ml puromycin was added to select 
for puromycin resistant colonies.   
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MCF7 DR-GFP stable cells were seeded at low density and transfected with either 
siRNA directed against BACH1 (Reagent A, 5’ AGCUUACCCGUCACA 3’ or Reagent 
B, 5’ GUACAGUACCCCACCUUAU 3’), BRCA1 (siRNA BRCA1 pool, Dharmacon), 
or a luciferase control (Dharmacon).  Twenty-four hours after siRNA transfection, cells 
were transfected (Fugene) with 10 μg of the pCMV-I-Sce1 vector. Cells were collected 
3-4 days following the final transfection and analyzed by flow cytometry.  In each case, 
the percentage of GFP positive cells was scored out of a total of 250,000 total viable 
events.  The shRNA lentiviral vectors were made by placing the BACH1 (A) sequence 
and the BRCA1 sequence 5’ AGTACGAGATTTAGTCAAC) into the FSIPPW lentiviral 
vector as described previously 109. 
 
MMC Sensitivity Assay and Chromosome Spreads 
MCF7 cells were transiently transfected as described above. Twenty-four hours after 
transfection, cells were seeded onto 96-well plates at 1 X 103 cells per well, incubated 
overnight, and then treated with a concentration range of MMC (Sigma). After incubation 
for 4 to 5 days, the percent growth was measured photometrically in a model 3550 
microplate reader (Perkin Elmer) as the relative growth (in luciferase units) using the Cell 
Titer glo-viability assay (Promega).  For quantitation, the luciferase units of each well 
were normalized to those obtained from untreated cells assumed to yield 100% cell 
survival, and were normalized to those obtained from a well without any cells, assumed 
to yield 0%.   
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Human mammary epithelial cells (HMEC) were infected with either eGFP or 
BACH1 (A) shRNA (see description above), treated with 0.05 µg/mL colcemid (Sigma) 
and incubated at 37°C for 1 hr.  Cells were collected, resuspended in 75 mM KCl, and 
incubated in a 37°C water bath for 18 minutes.  Swollen cells were then fixed in 3:1 
acetic acid and methanol for 45 minutes on ice.  The final fixation was repeated and fixed 
cells were dropped on coverslips, exposed to steam from an 80oC water bath, and dried 
cell-side-up on a 70 oC heat block.  Coverslips were stained with 0.3 µg/mL propidium 
iodide for 30 minutes, washed for 30 minutes, and mounted on glass slides.  Metaphase 
spreads were captured using an Olympus IX 70 Inverted Light microscope.  Data were 
collected as a Z series for deconvolution with 0.2 µm between planes. Images were 
deconvolved using MetaMorph software, no neighbors algorithm. 
 
Cell Culture  
MCF7 cells were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented 
with 10% fetal bovine serum (Gibco) and antibiotics.  MCF7 DR-GFP, FA-A fibroblasts 
(PD6914 + pMMP empty vector), FA-A reconstituted fibroblasts (PD6914 + FANCA), 
and FA-D2 fibroblasts (PD20) were grown as above with the addition of 1 µg/mL 
puromycin.  MCF7-DR-GFP cells, resistant to puromycin, were screened for the ability 
to show I-SceI induction of HR, since pooled populations would contain a number of 
cells that would not contribute to the HR assay. Normal human skin fibroblasts (PD846F) 
26 and FA-J fibroblasts (AG656) 33 immortalized with hTERT were grown in DMEM 
supplemented with 15% FBS and antibiotics.   
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Immunoprecipitation and Western blot assays  
Cells were harvested and lysed in lysis buffer (20 mM Tris [pH 8.0], 150 mM NaCl, 1 
mM EDTA, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride,10 µg/ml leupeptin, 10 
µg/ml aprotinin) for 30 min on ice.  For FANCD2 monoubiquitination assays cells were 
treated with 1 mM HU (Sigma) for 24 hours and lysed as above, but with 600 mM NaCl. 
Cell extracts were clarified by centrifugation for 10 min at 13,200 rpm.  The cell lysates 
were boiled in SDS loading buffer and DTT.  For precipitation assays, cells lysates were 
incubated with either protein A beads for I82 and E67 Abs, or with glutathione 
conjugated beads for BRCT-GST fusion protein, and incubated at 4°C for 2 hrs.  Beads 
were subsequently washed and boiled in SDS loading buffer.  Proteins were separated 
using SDS-PAGE and electrotransferred to nitrocellulose membranes. 
Western blot assays were carried out with a BRCA1 monoclonal Ab (MS110), 
BACH1 monocolonal Ab pool (1A3, 2G7 and IG5) 5 or BACH1 polyclonal Abs I82 
made vs. full-length BACH1-Flag protein 6, (and generated by R. Drapkin), E67 6, and 
E87 generated against epitopes 983-997 of BACH1, β-actin (Sigma) monoclonal Ab, and 
E35 rabbit anti-human FANCD2 antibody 23 for 2 hrs at 4°C.  Primary antibodies were 
detected with horseradish peroxidase-conjugated secondary antibodies (Amersham 
Biosciences) for 1 hr at RT.  All blots were detected with ECL-plus Western Blotting 
Detection System (Amersham Biosciences) using Biomax MR or XAR film (Kodak). 
Bradford assays were used to determine protein content (Bio-Rad). 
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Immunofluorescence Microscopy 
Cells were fixed with 2% paraformaldehyde in PBS for 20 min at RT, and were 
subsequently permeabilized with 0.2% Triton X-100 in PBS for 3 min at RT, and 
incubations with antibodies and washes were as previously described 5.  For 
immunostaining of γ−Η2ΑX or Rad51, MCF7 or FA-J cells were treated with 1 mM HU 
for 18 hrs and stained as above.  Mouse monoclonal anti-phospho-Histone  γ−Η2ΑX 
(Ser139) antibodies were purchased from Upstate. Polyclonal Rad51 Abs were purchased 
from Santa Cruz. Secondary Abs were either Rhodamine Red-conjugated AffiniPure 
Goat anti-mouse IgG or FITC-conjugated AffiniPure Goat Anti-rabbit IgG purchased 
from Code Jackson ImmunoReseach Laboratories INC. 
 
Sequencing 
Total RNA was purified from FA-J cells (Qiagen RNeasy) and RT-PCR was preformed 
as outlined by the manufacturer (Qiagen one step RT-PCR) using overlapping primers.  
The thermocycling conditions for amplification of cDNA were as follows: 50°, 30 min, 
95°, 15 min,  40 cycles each with a denaturing step at 94°C for 1 min, an annealing step 
at 50°C for 1 min, and extension step at 72°C for 1 min.    The reaction was completed 
with a final extension at 72°C for 10 minutes and a 4°C soak.  Genomic DNA was 
purified from FA-J cells (Qiagen DNeasy) and PCR was performed using intronic 
primers that flank the mutated region observed in exon 17.  The thermocycling conditions 
for amplification of genomic DNA were as follows: 95°C, 2 min, followed by 30 cycles 
each with a denaturing step at 95°C for 30 seconds, an annealing step at 50°C for 1 min, 
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and extension step at 72°C for 4 min.  The reaction was completed with a final extension 
at 72°C for 10 minutes and a 4°C soak.  Both RT-PCR and PCR products were separated 
on 1% agarose gels containing ethidium bromide and visualized with UV light.  PCR 
primer combinations were as follows (primers written in 5’-3’ orientation): 
 
A’) CCGCTTTATTTGCTCTCAGAAG and 
CTGTTCCAAAGCAATGACGTTTTCTAATCTGCTGT;  
A) ATGTCTTCAATGTGGTCTGAATATACAATT and 
ACACAGCCCGAGAACTAATACAA  
B) TTGCTAGATGGGAAAAACGG and AGAGATTCCGACCCTTGGGGCC  
C) GTTGGTACCATTGGGTCAGGC and TGATCTCCGCCCGTTTCAAAA  
D) ACAAAGAGAGTTAGCTGGTCAAGCTTTA and 
CAGCGGCCGCCTTAAAACCAGGAAACATGCCTTTATT  
bc) ATGGCAAAGTTCAGACCATTG and 
AAGTCCAGATATATAGCGACTTGGGTTATTCCT 
Forward Intron:  ATCTCTACCCTAAAAATATGTATATTC   
Reverse Intron:  CCAGTTCCTATGGTTCCAGTTAAATA   
PCR products were sequenced (Nucleic Acid Facility, UMMS) on both strands 
with the primers used to create the amplicon.  Additional primers were used for 
sequencing the region containing the noted mutations listed below: 
Forward 1: AGGAATAACCCAAGTCGCTATATATCTGGACTT 
Reverse 2: AAGTCCAGATATATAGCGACTTGGGTTATTCCT 
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Forward 2: CTTAATGTATCCATAAAGGAC 
Reverse 2: AAGGGCCCACTTGGTAGAGGTGAATTTTTGGT 
  
Lentiviral Infection and G2/M accumulation assay 
FA-J cells were infected with either pLENTI6/v5-DEST (Invitrogen) empty vector or 
pLENTI6/v5-DEST + WT BACH1 (gift of J. Chen) and stable cells were selected with 7 
µg/mL Blasticidin (Invitrogen).  PD846F (Normal), FA-J, FA-J + vector,  and FA-J + 
WT BACH1 cells immortalized with hTERT were either mock treated or treated with 0.5 
µg/mL of melphalan (Sigma) and incubated for 65 hrs.  Cells were fixed with 90% 
methanol in PBS and were then incubated 10 min with PBS containing 30 U/ml DNAse-
free RNAse A and 50 µg/ml propidium iodide.  1X104 cells were analyzed using a 
FacsCalibur instrument (Becton-Dickinson, San Jose, CA).  Aggregates were gated out 
and  the percentage of cells in G2/M was calculated using FlowJo software. 
 
Acknowledgments: 
We thank UMASS Medical School and the Mary Kay Ash Foundation for financial 
support.  We are grateful to Ronny Drapkin (Dana-Farber Cancer Institute, Boston, MA) 
for the I82 Ab and to Alan D’Andrea (Dana-Farber Cancer Institute, Boston, MA) for 
various FA cell lines. We thank Steve Doxsey and Jack Rosa (UMASS Medical School, 
Worcester, MA) for their time and help visualizing chromosome spreads.  We thank 
Junjie Chen and Xiaochun Yu (Mayo Clinic, University of Minnesota) for the BACH1 
lentivirus vector. 
 
 85
CHAPTER IV 
 
The FANCJ/MutLα interaction is required for correction of the ICL-
response in  FA-J cells 
 
Abstract 
 
FANCJ was first linked to hereditary breast cancer through its direct interaction 
with BRCA1. FANCJ was also recently identified as a FA gene product, establishing 
FANCJ as an essential tumor suppressor.  Similar to other FA cells, FANCJ-null (FA-J) 
cells accumulate a 4N DNA content in response to DNA ICLs.  This accumulation is 
corrected by re-introduction of wild-type FANCJ.  Here, we show that FANCJ interacts 
with the MMR complex MutLα, composed of PMS2 and MLH1.  Specifically, FANCJ 
directly interacts with MLH1 independent of BRCA1 through its helicase domain.  
Genetic studies reveal that FANCJ helicase activity and MLH1 binding, but not BRCA1 
binding, are essential to correct the FA-J cells ICL-induced 4N DNA accumulation and 
sensitivity to ICLs.  These results suggest that the FANCJ/MutLα interaction, but not the 
FANCJ/BRCA1 interaction, is essential for establishment of a normal ICL-induced 
response.  The functional role of the FANCJ/MutLα complex demonstrates a novel link 
between FA and MMR and predicts a broader role for FANCJ in DNA damage signaling 
independent of BRCA1.  
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Introduction 
In the absence of DNA repair proteins, cell cycle checkpoints and/or DNA 
damage repair pathways are not properly activated.  This inability to actively respond to 
DNA damage can lead to massive chromosomal damage and even cell death.  In some 
cases, mutations in DNA repair proteins can contribute to multiple cancer syndromes.  
Studies on the genetic causes of the cancer-prone syndrome FA revealed that gene 
mutations associated with hereditary breast cancer were also associated with FA.  For 
example, the hereditary breast cancer gene, BRCA2 was shown to be the gene defect in 
the FA-D1 patient complementation group, revealing that BRCA2 was FANCD1 22.  
Likewise, FANCJ (formally called BACH1/BRIP1) was recently identified as the gene 
defect in the FA-J patient complementation group 99,105,106, and was initially linked to 
hereditary breast cancer.  This link was based on its direct binding to BRCA1 and 
through the identification of two breast cancer patients with mutations in FANCJ, which 
also altered its helicase activity in vitro 5,6.  This connection was furthered by the finding 
that FANCJ mutations confer a two-fold increase in the risk of developing breast cancer 
7.  
While other FA genes have not been linked to breast cancer, the network of at 
least 12 genes (designated FANCA to FANCL) are critical for maintaining chromosomal 
integrity 108.  Although the molecular function of these proteins is not clear, several gene 
products, including FANCA, B, C, D, E, F, G, L, and M, form a nuclear core complex 
(the FA core complex), that is required for monoubiquitination of FANCD2.  The FA 
proteins BRCA2/FANCD1 and FANCJ are not required for this event and are considered 
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downstream of FANCD2 monoubiquitination.  Nevertheless, all FA proteins contribute to 
processing interstrand-cross-links (ICLs) 108. Consequently, in the absence of FA 
proteins, ICL-treatment leads to reduced viability and an accumulation of cells with a 4N 
DNA content representing cells in either late S or G2/M.  This ICL-induced cell cycle 
progression defect and sensitivity to ICLs is restored upon re-introduction of the missing 
FA gene 54,122-127.  However, the FA-related function or associated partners required for a 
proper ICL-response is not known.  
Consistent with other FA cells, FANCJ-null (FA-J) cells have an ICL-induced cell 
cycle progression defect that can be corrected upon re-introduction of wild-type (WT) 
FANCJ cDNA 99.  Unlike the majority of FA proteins, FANCJ has defined domains.  
Specifically, FANCJ binds directly to BRCA1 5 and FANCJ is a DNA helicase 6. 
Dissecting the importance of these domains could further our understanding of how FA 
proteins function in an ICL-induced response.  Attempts to define the functions of 
FANCJ domains have been limited to chicken DT40 cells where the FANCJ /BRCA1 
interaction is not conserved 107. If FANCJ operates independent of BRCA1 for a 
particular function, a remaining question will be whether FANCJ forms a complex with 
other proteins independent of BRCA1 to perform that function.  
Here, we investigated whether FANCJ helicase activity or the FANCJ interaction 
with two distinct proteins was required for restoring FANCJ’s ICL-response.  
Specifically, we identified that FANCJ interacts with the MLH1 MMR protein, 
independent of BRCA1.  Our findings demonstrate for the first time that the FANCJ 
/MLH1 interaction is as critical as FANCJ helicase activity for restoring a normal cell 
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cycle progression and resistance to ICLs.  In contrast, disruption of the FANCJ /BRCA1 
interaction does not interfere with establishment of the ICL-response, suggesting that 
FANCJ functions in distinct complexes to facilitate multifaceted DNA repair functions.  
 
Results 
FANCJ functions independently of BRCA1 to correct FA-J null cells 
We had previously shown that introduction of WT FANCJ cDNA into FA-J cells 
corrects the ICL-induced cell cycle progresssion defect 99.  However, it is unclear how 
FANCJ contributes to the ICL-response to restore the FA pathway especially given that 
FANCJ’s role in the FA pathway appears to be independent of BRCA1, at least in 
chicken cells 107.  To verify and extend this finding, we addressed whether FANCJ 
binding to BRCA1 was required to correct the ICL-induced cell cycle progression defect 
in FA-J cells. We reconstituted FA-J cells with vector, WT, or the S990A FANCJ 
construct that is ablated for BRCA1 binding 95 (Figure 4-1A and B).  Both WT and 
S990A versions of FANCJ corrected the ICL-induced cell cycle progression defect 
observed in FA-J cells compared to vector alone (Figure 4-1C).  These data support the 
finding that FANCJ operates independent of BRCA1 to correct FA-J cells.    
 
FANCJ is physically linked to the MutLα complex independent of BRCA1 
Since FANCJ binding with BRCA1 was not required to correct the ICL-induced 
cell cycle progression defect in FA-J cells, we set out to identify additional FANCJ 
interacting partners that may function with FANCJ in this ICL-induced response.  A WT 
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double-tagged FANCJ construct was used to create a stable line of HeLa S3 cells.  Using 
a two-step immunoaffinity strategy, the double-tagged FANCJ was sequentially 
immunopurified 147.  Interacting proteins co-purifying with the double-tagged WT 
FANCJ were eluted and visualized by silver stain. FANCJ migrated at the expected 
~140KD size as well as a single larger species that appears to derive from the vector 
(Figure 4-2A). Individual bands were excised from the gel and analyzed by mass 
spectrometry (LC-MS/MS).  As expected, FANCJ co-purified with BRCA1 that was 
identified as the 250kD band.  Unique partners were identified, including the MMR 
proteins, MLH1 and PMS2, which form the MutLα heterodimer 148 (Figure 4-2A).  
Western blot analyses using specific antibodies confirmed the presence of these proteins 
(Figure 4-2B). The ~140kD FANCJ band was similar in size to the endogenous FANCJ 
and was clearly detected by Flag and FANCJ Antibodies (Abs) (Supplemental Figure 4-
7) and therefore, exclusively depicted in the FANCJ Western blot (Figure 4-2B).  To 
determine whether the MutLα complex associated with the native FANCJ protein, MCF7 
cell extracts were immunoprecipitated (IPed) with FANCJ antibodies (Abs) E67 and E47, 
and the presence of coprecipitating MLH1, PMS2, and BRCA1 protein was evaluated by 
Western blot (Figure 4-2C).  As a control, we demonstrated that the MutLα complex was 
not precipitated with preimmune Abs (PI) or with FANCJ Abs in 293T cells, which lack 
expression of the MutLα complex 149. Moreover, FANCJ was not precipitated with the 
MLH1 Abs in FA-J cells, which lack expression of FANCJ, unless FANCJ was re-
introduced (see Figure 4-6A).  Furthermore, the interaction between FANCJ and the 
MutLα complex was stable in HeLa cells in the presence or absence of DNA damage 
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(Figure 4-2D).  In a reciprocal IP experiment with anti-MLH1 Ab, FANCJ was readily 
co-precipitated, but BRCA1 was more difficult to detect (Figure 4-2C).  
Because MLH1 was reported in a BRCA1 complex 49,150, we examined whether 
BRCA1 mediated the interaction between FANCJ and the MutLα complex.  Expression 
of BRCA1 was stably suppressed in MCF7 cells by a shRNA vector, as previously 
demonstrated 99.  In cells expressing a control shRNA eGFP or the BRCA1 shRNA, 
FANCJ antibodies efficiently co-precipitated the two components of the MutLα complex 
(Figure 4-3A), suggesting that FANCJ binds the MutLα complex independent of 
BRCA1.  In support of this finding, the helicase domain of FANCJ was required for 
MLH1 binding while a C-terminal region of FANCJ was required for BRCA1 binding 
(Figure 4-3B).  To further assess the nature of the FANCJ/MLH1 interaction, we 
incubated recombinant FANCJ or BRCA1 with MLH1 that had been translated in vitro.  
MLH1 and FANCJ were precipitated by their corresponding Abs, and their interactions 
were analyzed by Western blot.  FANCJ and MLH1 proteins were co-precipitated with 
both FANCJ and MLH1 IPs, whereas BRCA1 was robustly precipitated only in the 
FANCJ IP (Figure 4-3C). The direct interaction between FANCJ and MLH1 was 
confirmed by ELISA assay using purified recombinant proteins and FANCJ bound 
MLH1 in a protein concentration dependent manner (Figure 4-3D).  Furthermore, the 
interaction of FANCJ and MLH1 was demonstrated to be DNA-independent as 
evidenced by the similar colorometric signal observed for FANCJ/MLH1 interaction in 
the presence of EtBr or DNaseI (Figure 4-3E).  These results suggest that FANCJ makes 
direct contacts with MLH1, independent of PMS2 or BRCA1. 
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Lysines 141 and 142 of FANCJ are required for the FANCJ/MLH1 interaction 
Next, we sought to disrupt FANCJ binding to MLH1 in order to test the 
functional significance of the FANCJ/MLH1 interaction for FANCJ function in the ICL 
response. To do so, we mapped the domain on FANCJ required for MLH1 binding.  We 
generated several FANCJ-myc fusion proteins of varying length and expressed them in 
MCF7 cells (Figure 4-4A and C).  FANCJ co-precipitated with MLH1 except when 
FANCJ residues 140-145 were absent (Figure 4-4A).  To assess the importance of 
residues 140-145 for binding MLH1 within the context of the full-length FANCJ protein, 
we generated three independent FANCJ mutant constructs that converted lysine 141 and 
142 to alanine (K141/142A), glutamine 143 to a glutamic acid (Q143E), or serine 145 to 
an alanine (S145A).  While the WT FANCJ and all three mutant versions were expressed 
and efficiently co-precipitated BRCA1, the K141/142A version demonstrated a dramatic 
reduction in the co-precipitation of MLH1 (Figure 4-4B) suggesting that these two 
lysines were required for MLH1 binding.  
We considered that the K141/142A mutation in FANCJ could have not only 
disrupted MLH1 binding, but also FANCJ helicase activity. Thus, we generated 
recombinant versions of WT 6 and the K141/142A FANCJ proteins to assess whether this 
mutant version was enzymatically active.  The recombinant K141/142 FANCJ protein 
was detected as a single Coomassie stained band analyzed by SDS-PAGE that co-
migrated with the WT FANCJ recombinant protein (Figure 4-5A and D).  The DNA 
unwinding activity of K141/142A FANCJ on a forked duplex DNA substrate was 
compared to unwinding activity of WT FANCJ.  Both K141/142A FANCJ and WT 
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FANCJ were found to be proficient in unwinding whereas K52R FANCJ, as previously 
demonstrated, failed to unwind the forked duplex substrate 139 (Figure 4-5B).  
Furthermore, K141/142A FANCJ and WT FANCJ unwound the forked duplex substrate 
in a protein concentration dependent manner achieving 90% of unwound substrate at the 
highest helicase concentration tested (Figure 4-5C).  Thus, the K141/142 mutant only 
disrupts MLH1 binding, but not FANCJ helicase activity in vitro. 
 
FANCJ function depends on MLH1 binding to correct FA-J cells 
Next, we tested the ability of K141/142A FANCJ cDNA to correct the cell cycle 
progression defect in FA-J cells.  We used retroviral infection to stably infect FA-J cells 
with cDNA encoding the vector, WT, K141/142A, or K52R Flag/HA-tagged FANCJ 
constructs, which expressed similarly (Figure 4-6A).  Moreover, an MLH1 IP 
demonstrated that the MLH1/PMS2 complex was intact in FA-J cells and was able to 
precipitate the reconstituted FANCJ (Figure 4-6A).  As before MLH1 co-IPed with WT 
FANCJ, but was dramatically reduced in FA-J cells with the K141/142A mutant FANCJ 
(Figure 4-6A).  FA-J cells containing vector, WT, K52R, or K141/142A FANCJ were 
treated with melphalan to induce ICLs as described 99.  The proportion of vector-
containing FA-J cells with 4N DNA content increased after melphalan treatment, similar 
to previous experiments.  As before the proportion of WT FANCJ-containing FA-J cells 
with 4N DNA content (~30%) was about half that of vector-containing cells (~70%).  We 
found that cells containing the catalytically inactive FANCJ helicase (K52R) failed to 
correct the 4N accumulation defect (~66%).  Likewise, the proportion of K141/142A 
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FANCJ-containing FA-J cells with 4N DNA content (~68%) resembled that of vector-
containing FA-J cells, suggesting that introduction of K141/142A FANCJ did not correct 
the cell cycle progression defect in FA-J cells (Figure 4-6B). These data suggest that the 
FANCJ/MLH1 interaction is essential for restoration of the FA pathway in FA-J cells.    
To further confirm and examine the importance of FANCJ binding to MLH1 for 
the ICL-induced response, we assessed whether FANCJ binding to MLH1 was required 
for FANCJ to correct the ICL-induced sensitivity of FA-J cells.  However, the ability of 
WT FANCJ to correct the ICL sensitivity of FA-J cells had not been previously reported.  
Thus, we first tested and confirmed that re-introduction of WT FANCJ corrected the ICL-
sensitivity of FA-J cells treated with MMC.  The vector reconstituted FA-J cells were 
more sensitive to MMC than the WT FANCJ reconstituted cells with an IC50 of 250mM 
and ~ 900mM MMC, respectively (Figure 4-6C).  In contrast to WT, both the 
K141/142A, and K52R FANCJ reconstituted FA-J cells were sensitive to ICLs with an 
IC50 of less than 250mM MMC.  Moreover, the K141/142A FANCJ reconstituted FA-J 
cells were more sensitive than the vector or K52R FANCJ reconstituted FA-J cells (P< 
0.01).  As before, the S990A FANCJ corrected the ICL-response similar to WT.  
Although the correction of the ICL sensitivity was greater with the S990A FANCJ than 
with the WT FANCJ, at 250mM MMC the values were not significantly different (with 
P-values between 0.0027-0.22) (Figure 4-6C).  These findings clearly demonstrate that 
both FANCJ helicase activity and FANCJ binding to MLH1 are required for FANCJ to 
functionally correct the ICL sensitivity of FA-J cells.     
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Discussion 
In this study, we addressed whether FANCJ helicase activity or different FANCJ 
complexes are essential for FANCJ’s function in the ICL response.  Specifically, we have 
shown that FANCJ forms a complex with the MutLα heterodimer, which is composed of 
the MMR proteins MLH1 and PMS2.  FANCJ directly interacts with MLH1 independent 
of BRCA1, and this DNA-independent interaction is within the FANCJ helicase domain, 
C-terminal to nucleotide binding box 1, and includes lysines 141 and 142.  This is the 
first report that demonstrates that a direct interaction between FANCJ and MLH1 is as 
essential for the ICL-induced response as the FANCJ helicase activity.  Furthermore, our 
data suggest that formation of a FANCJ/BRCA1 complex is not required for re-
establishment of the ICL induced response.  
Following exposure to ICLs, ATR is activated and initiates a signal cascade 
through the phosphorylation of downstream substrates ultimately leading to checkpoint 
activation, DNA damage repair, and/or apoptosis.  Intriguingly, MMR proteins were 
recently proposed to act as direct sensors of DNA methylation and initiate the intra S-
phase checkpoint by helping to recruit ATR-ATRIP to sites of DNA damage 151.  
Furthermore, MMR proteins have been implicated in sensing and repairing ICLs.  In 
particular, the MutSα complex was shown to bind to intrastrand crosslinks produced by 
cisplatin 152,153, and the MutSβ complex was shown to be involved with the removal of 
ICLs produced by psoralen 154. This study now suggests that MLH1 binding to FANCJ is 
functionally important for the ICL-induced response, as the FANCJ K141/142A mutant, 
defective in MLH1 binding, fails to correct FA-J cells.  
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Given that the FANCJ/MLH1 interaction is intact in other FA cells, including FA-
A, FA-D2, and FA-D1 (Supplemental Figure 4-9), loss of this complex is not a general 
feature of FA cells.  However, it remains to be determined whether additional FA-MMR 
interactions are altered.  Moreover, similar to FANCJ deficiency, MLH1 deficiency does 
not affect the ATR-mediated FANCD2 monoubiquitination (Supplemental Figure 4-8) 26; 
33,99,107, suggesting that the FANCJ/MLH1 interaction is not essential for FA-pathway 
activation.  
The question remains as to how FANCJ or MMR proteins function in the ICL-
response.  Since FA-J cells arrested DNA synthesis in response to ICL-treatment similar 
to WT FANCJ corrected FA-J cells (data not shown), the 4N DNA accumulation may not 
reflect a failed intra S-phase checkpoint as reported in other FA cells 53,54.  Instead, the 
ICL-induced 4N DNA accumulation may represent an inefficient or delayed repair of 
ICLs 52.  Perhaps essential to the survival of FA cells is the extra time to repair and 
recover in order to prevent ICL-induced apoptosis.  In fact, treatment of FA-J cells with 
ICL agents does not lead to a dramatic cell death as compared to WT FANCJ corrected 
FA-J cells, but rather a sustained 4N DNA accumulation leads to reduction in cell 
number (data not shown).  Thus, the sensitivity of FA-J cells to ICLs may stem from the 
4N DNA accumulation combined with delayed re-entry into the cell cycle 52.   
The enhanced ICL sensitivity of FA-J cells expressing the K141/142A FANCJ 
mutant compared to vector suggests that loss of FANCJ binding to MLH1 impacts the 
ICL-response more than loss of FANCJ alone.  If MLH1 serves to localize or regulate 
FANCJ helicase at sites of DNA damage, the K141/142A FANCJ mutant may be more 
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disruptive to repair.  The MLH1 homologue in E. coli, MutL binds the DNA helicase 
UvrD gene product Helicase II 155,156 and stimulates its helicase activity 157,158. 
Conceivably, for ICL repair, MMR complexes including MutLα, mobilize or regulate 
FANCJ helicase activity to unwind DNA in the vicinity of the DNA damage to facilitate 
repair processes.  Thus, disruption of FANCJ helicase activity or MLH1 binding will 
interfere with ICL-induced signaling.  We did not detect an effect of the MutLα complex, 
inhibitory or stimulatory, on FANCJ catalyzed unwinding of a forked duplex, 5’ flap, or 
Holliday Junction substrate (data not shown).  However, it is possible that regulation of 
FANCJ helicase activity by MLH1 may require the support of additional MMR proteins.  
It is also possible that the physical interaction between FANCJ and MLH1 may serve a 
non-catalytic role in mediating the ICL-response.   
The connection of MMR proteins to the ICL-response has been controversial 
given the ambiguity of results relating to the relative sensitivity or resistance of MMR 
deficient cells to agents that induce ICLs 159,160. We found that suppression of the MutLα 
complex in MCF7 cells did not lead to MMC sensitivity (data not shown).  Most likely, 
to uncover the distinct role of the MutLα complex in the ICL-induced response, 
separation-of-function mutants will be required.  Conceivably, MLH1 binding to FANCJ 
is required for MLH1’s ICL function, but loss of other MLH1 functions mask any defect 
in its ICL-response.  Ultimately, it will be critical to establish whether a FANCJ/MLH1 
complex facilitates ICL-repair by promoting HR or other repair functions.  While 
ablation of BRCA1 binding to FANCJ may not affect the ability of FANCJ to correct the 
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defective response of FA-J cells, the timing or mechanism of repair may be altered.  
Efforts are underway to address this possibility. 
In conclusion, these studies have provided the first evidence for a role of the 
FANCJ/MutLα complex in the ICL induced response.  Further study of the role of 
FANCJ, BRCA1, and MMR proteins in this process should advance the understanding of 
how ICL-induced responses are regulated to preserve genomic integrity.  
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Figure 4-1: The FANCJ/BRCA1 interaction is dispensable for correction of the 4N 
DNA accumulation defect in FA-J cells.  A) FA-J cells were reconstituted with vector, 
WT or S990A,  and FANCJ expression was analyzed in whole cell extracts (WCE) by 
immunoblot.  ß-actin serves as a loading control for the WCE samples. B) 
Immunoprecipitations with FANCJ (E67) were analyzed by Western blot with the noted 
Abs. C) FA-J cells reconstituted with vector, WT or S990A FANCJ were either left 
untreated or treated with melphalan and the percentage of cells with 4N DNA content  
was analyzed by FACS.  The percent of cells with 4N DNA content after ICL-treatment 
was averaged for each cell line from four independent experiments with standard 
deviation (SD) indicated by error bars. 
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Figure 4-2: FANCJ interacts with the MMR proteins MLH1 and PMS2. A) Silver 
stained gel of the WT FANCJ (F) compared to a Vector (V) purified complexes from 
HeLa S3 cells by consecutive Flag and HA purification steps (Flag/HA). Identified 
unique bands are indicated and FANCJ is observed as two species, the 140kD band is 
labeled. B) Western blot detection of Flag/HA purified FANCJ complexes. C) 
Immunoprecipitations with either FANCJ (E67 or E47) or MLH1 Abs from MCF7 or 
293T cells were analyzed by Western blot with the noted Abs.  D) HeLa cells were either 
left untreated or treated with 1mM HU for 24hr or 2.4ug/mL MMC for 1hr.  HeLa cell 
lysates were immunoprecipitated with preimmune (PI) or FANCJ Abs followed by 
Western blot analysis with the noted Abs.  
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Figure 4-3: FANCJ helicase domain associates with the MutLα complex independent 
of  BRCA1 and through a direct interaction with MLH1. A) MCF7 cells were stably 
infected with a lentivirus encoding shRNA for either eGFP or BRCA1.  FANCJ IP was 
performed followed by Western blot for the indicated proteins. B) MCF7 cells were 
transiently transfected with pCDNA3 vectors containing no insert (-), full length FANCJ 
(FL), helicase domain including amino  acid residues 1-882 (HD) or C-terminus 
including residues 882- 1249 (CT) of FANCJ, then immunoprecipitated with the Myc Ab 
(9E10). Arrows designate the respective FANCJ myc-tag species.  Immunoglobulin (IgG) 
is shown. C) Western blot of the indicated IP experiments in which in vitro translated 
MLH1 was incubated with recombinant FANCJ or BRCA1 proteins. D) Purified 
recombinant MLH1 or BSA was coated onto ELISA plates.  Following blocking with 3% 
BSA, the wells were incubated with increasing concentrations of purified recombinant 
FANCJ (0-40 nM) for 1 hr at 30 oC, and bound FANCJ was detected by ELISA using a 
rabbit polyclonal Ab against FANCJ followed by incubation with secondary horseradish 
peroxidase (HRP)-labeled antibodies and OPD substrate.  Data points are the mean of 
three independent experiments performed in duplicate with SD indicated by error bars. E) 
ELISA was performed as described in Panel D using 4.9 nM FANCJ alone or in the 
presence of EtBr (50 μg/ml) or DNaseI (2 μg/ml).  BSA (3%) was used as a control 
instead of MLH1 during the coating step. 
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Figure 4-4: MLH1 binding to FANCJ requires lysine residues 141 and 142.  A) Myc 
(9E10) IP experiments were performed from MCF7 cells that were transfected with 
vector alone (-), full-length FANCJ (FL), and the different FANCJ constructs (A-G) 
shown in C, followed by Western blot with MLH1, and Myc Abs. The asterisk denotes 
the migration of the different myc-tagged FANCJ species.  B) Myc IP experiments were 
performed from MCF7 cells that were transfected with vector alone (-), FL, H, I and J 
FANCJ constructs shown in C, followed by Western blot with the indicated Abs. C) The 
different FANCJ constructs are shown with a positive (+) or negative (-) to indicate 
binding to MLH1.  
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Figure 4-5: The K141/142A FANCJ mutant maintains robust helicase activity.  A) 
Recombinant K141/142A FANCJ protein was immunoprecipitated with Flag antibodies 
and eluted using Flag peptide.  The purity of the protein sample was visualized by 
Coomassie stain and arrow denotes both WT and K141/142A FANCJ species B) Helicase 
reactions (20 µl) were performed by incubating the indicated concentrations of WT, 
K141/142A, or K52R FANCJ as with 0.5 nM forked duplex DNA substrate at 30 oC for 
15 min in the presence of ATP (2 mM) under standard helicase assay conditions as 
described under “Materials and Methods.”  The duplex substrate runs at the top of the gel 
and the unwound DNA fragment runs below as shown. Filled triangle, heat-denatured 
DNA substrate control. A phosphorimage of a typical gel is shown.  C) Quantitative 
helicase data represent the mean of at least three independent experiments with standard 
deviation (SD) indicated by error bars.  Open squares, FANCJ-WT; filled squares, 
FANCJ-K141/142A.  D)  Recombinant WT, K141/142A, and K52R proteins used in B 
were separated by SDS-PAGE and analyzed by Western blot using FANCJ specific 
antibodies. 
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Figure 4-6: MLH1 binding to FANCJ is essential to correct FA-J cells.  A) FA-J cells 
were reconstituted with empty vector, WT, K141/142A, or K52R FANCJ vectors and 
FANCJ expression was analyzed by whole cell extracts, β-actin serves as a loading 
control for the WCE samples. Western blot shows the presence of the indicated proteins 
from both MLH1 IPs and FANCJ IPs from FA-J cells reconstituted with vector, WT, or 
K141/142A FANCJ.  B) FA-J cell lines reconstituted with empty vector, WT, 
K141/142A, or K52R FANCJ were either left untreated or treated with melphalan.  The 
percent of cells with 4N DNA content after ICL-treatment was averaged for each cell line 
from four independent experiments with standard deviation (SD) indicated by error bars.  
C) FA-J cells reconstituted with vector, WT, K141/142A, K52R, or S990A FANCJ were 
seeded on 24 well plates and incubated overnight under normal growth conditions.  The 
cells were then treated with the indicated doses of MMC and incubated for eight days.  
On the final day, the cells were counted and the percentage of live cells was calculated.  
Experiments were performed in triplicate and a representative graph is shown.  The IC50 
dose for the FA-J vector (250mM) was compared for all mutants and error bars represent 
the standard deviation. 
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Supplemental Figure S4-7: The 140Kd  FANCJ species is recognized by the Flag Ab 
and migrates similarly to endogenous FANCJ.  Left panel: HeLa  cells  reconstituted 
with empty vector (V), WT FANCJ (F), or uninfected HeLa cells were  lysed  
and immunopreciptated with Flag or FANCJ (e67) Abs and analyzed by Western blot 
using FANCJ Ab. Right panel: FA-J cells reconstituted with empty vector(V), WT 
FANCJ (F), were lysed and analyzed by Western blot using Flag Ab.  
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Supplemental Figure S4-8: FANCD2 monoubiquitination is intact in MLH1-deficient 
cells.  HCT116, HEC-1A, and HeLa cells were either left untreated or treated with 1 mM 
HU for 24 hours, lysed with 600mM NETN, and analyzed by Western blot with the 
indicated Abs. Both long (L) and short (S) forms of FANCD2 are noted.  
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Supplemental Figure S4-9: FANCJ/MLH1 interaction is unaltered in other FA cell 
lines.  FA cells were lysed in 150mM NETN and lysates were normalized.  
Immunopreciptations were performed using FANCJ Ab (E47) and precipitates were 
analyzed by Western blot using FANCJ and MLH1 specific Abs. 
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Materials and Methods 
Cell lines  
HeLa, MCF7, 293T and HeLa S3 cells were grown in DMEM supplemented with 10% 
fetal bovine serum and penicillin/streptomycin (100 U/mL each). FA-J (EUFA30-F) cells 
were cultured as previously described 99.  HCT116 cells were grown in McCoy’s 5A 
medium supplemented with 10% fetal bovine serum and penicillin/streptomycin (100 
U/mL each).  Hi5 insect cell were grown in Grace’s Insect Media supplemented with 
10% Fetal Bovine Serum and 1% genetemycin at 28°C without C02. FA-J cells were 
infected with the pOZ retroviral vector 147 containing no insert, WT, K141/142A, or 
K52R FANCJ inserts, or with the lentiviral vector pLentiV5 (Invitrogen) vector, 
containing no insert, WT, or S990A FANCJ inserts.  Stable FA-J pOZ cell lines were 
generated by sorting pOZ infected cells with anti-IL-2 magnetic beads (Dyna Beads) and 
expanding IL-2 positive cells.   Stable FA-J pLenti cell lines were generated through 
blasticidin selection (7μg/mL). 
 
Purification of a FANCJ complex 
A FANCJ complex was purified from nuclear extracts (NE) derived from ~8 X109 HeLa 
cells stably expressing the double tagged-FANCJ by two step immunoaffinity 
chromatography according to the standard method 147.  Flag-HA double purified material 
was electrophoresed in 3-8% Tris-Acetate Gel (Invitrogen). Individual Silver-stained 
bands were excised and subsequently analyzed by Mass spectrometry (Genomine Inc., 
South Korea). 
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Immunoprecipitations, immunoblotting and antibodies  
Cells were harvested and lysed in 150mM NETN lysis buffer (20 mM Tris [pH 8.0], 150 
mM NaCl, 1 mM EDTA, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride, 10µg/ml 
leupeptin, 10 µg/ml aprotinin) for 30 min on ice. Cell extracts were clarified by 
centrifugation.  The cell lysates were boiled in SDS loading buffer.  For 
immunoprecipitation assays cells lysates were incubated with protein-A beads and either 
FANCJ (E67 or E47), MLH1 (BD Bioscience) or Myc (9e10) Abs at 4°C for 2 hr.  Beads 
were subsequently washed and boiled in SDS loading buffer.  Proteins were separated 
using SDS-PAGE and electrotransferred to nitrocellulose.  Membranes were blocked in 
5% milk PBS/tween and incubated with primary Ab for 1hr.  Abs for Western blot 
analysis included anti-MLH1 (BD Bioscience,1:500), anti-PMS2 (BD Biosciences 
1:200), anti-BRCA1(ms110, hybridoma cell,1:3), anti-FANCJ (Monoclonal pool 2G7, 
2C10,1B4), anti-FANCD2 (Fanconi Anemia Research Foundation), and Myc (9E10, 
hybridoma cell, 1:3). Membranes were washed, then incubated with horseradish 
peroxidase-linked secondary antibodies (Amersham,1:5000), and detected by 
chemiluminescence (Amersham). 
 
4N DNA content accumulation assay  
FA-J stable cell lines were either treated with 0.5 µg/ml of melphalan (Sigma) or left 
untreated and incubated for 65 hr. Cells were fixed with 90% methanol in PBS and were 
then incubated 10 min with PBS containing 30 U/ml DNase-free RNase A and 50 µg/ml 
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propidium iodide. 1 x 104 cells were analyzed using a FACs Calibur instrument (Becton-
Dickinson, San Jose, CA). Aggregates were gated out and the percentage of cells with 4N 
DNA content was calculated using Modfit software. 
 
Plasmid construction and in vitro translation  
The WT and S990A FANCJ pLentiviral vectors were a gift of J. Chen 95. The pCDNA3-
myc.his vector (Invitrogen) was digested by Not1/Apa1 and different FANCJ fragments 
generated by PCR and digested Not1 and Apa1 were inserted. Primers are available upon 
request. The WT FANCJ pOZ-FH vector was generated by PCR cloning.  Specifically, 5’ 
Xho1 and a 3’ Not1 restriction sites were added by using primers: 5'-3' 
CGCTCGAGGCCACCATGTCTTCAATGTGGTCTGAATATACAATT  and 5'-3' 
CAGCGGCCGCCTTAAAACCAGGAAACATGCCTTTATT.  The PCR product was 
digested XhoI and NotI and subcloned into the pOZ-FH vector. The K52R, S990A, and 
K141/142A pOZ vectors were generated with the QuickChange Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA) by using the FANCJ-pOZ as a template and 
the following primers: (K52R) 5'-3' 
CCCACAGGAAGTGGAAGGAGCTTAGCCTTAGCC and 5'-3' 
GGCTAAGGCTAAGCTCCTTCC-ACTTCCTGTGGG; (S990A)5’-3’ 
TCCAGATCCACAGCCCCAACTTTCAAC and 5’-3’ 
GTTGAAAGTTGGGGCTGTGGATCTGGA. (K141/142A)  5'-3' 
GCAAAGTTATCTGCT GCGGCACAGGCATCCATATAC and 5'-3' 
GTATATGGATGCCTGTGCCGCAGCAGATAACTTTGC. The same set of primers 
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were used to generate the K141/142 A-pCDNA3 and K141/142 A-pVL132 by using the 
WT FANCJ pCDNA3myc.his 5 and pVL132Flag tagged 6 constructs respectively.  The 
Q143E and S145A pCDNA3 were generated with the QuickChange Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA) by using the following primers: (Q143E)5’-3’  
GCTGCAAAGTTATCTGCTAAGAAAGAGGCATC CATATACAG and 5’-3’ 
CTGTATATGGATGCCTCTTTCTTAGCAGATAACTTTGCAGC; or (S145A) 5’-3’ 
TCTGCTAAGAAACAGGCAGCCATATACAGAGAT GAA and 5’-3’  
TTCATCTCTGTATATGGCTGCCTGTTTCTTAGCAGA.  All DNA constructs were 
confirmed by DNA sequencing. MLH1 protein was synthesized in vitro by coupled 
transcription and translation using the T7 Quick-coupled TnT kit (Promega) and MLH1 
pCDNA3 vector as a template 161 gift of Guido Plotz (Homburg/Saar, Germany). 
 
ELISA studies  
Purified recombinant MLH1 protein was diluted to a concentration of 1 ng/µl in 
Carbonate buffer (0.016 M Na2CO3, 0.034 M NaHCO3, pH 9.6) and added to appropriate 
wells of a 96-well microtiter plate (50 μl/well), which was incubated at 4 oC.  3% Bovine 
serum albumin (BSA) was used in the coating step for control reactions.  The samples 
were aspirated, and the wells were blocked for 2 hr at 30 oC with Blocking buffer 
(phosphate buffered saline, 0.5% Tween 20 and 3% BSA).  The procedure was repeated.  
Purified recombinant FANCJ protein was diluted in Blocking buffer, and the indicated 
concentrations were added to the appropriate wells of the ELISA plate (50 μl/well), 
which was incubated for 1 hr at 30 oC.  For ethidium bromide (EtBr) or DNaseI 
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treatment, 50 μg/ml EtBr or DNaseI (2 μg/ml) was included in the incubation with 
FANCJ during the binding step in the corresponding wells.  The samples were aspirated, 
and the wells were washed five times before addition of rabbit polyclonal anti-FANCJ 
antibody (Sigma, B-1310) that was diluted 1: 5,000 in Blocking buffer.  Wells were then 
incubated at 30 oC for 1 hr.  Following three washings, horseradish peroxidase-
conjugated anti-rabbit secondary antibody (1: 5,000) was added to the wells, and the 
samples were incubated for 30 min at 30 oC.  After washing five times, any FANCJ 
bound to the immobilized MLH1 was detected using OPD substrate (Sigma).  The 
reaction was terminated after 3 min with 3 N H2SO4, and absorbance readings were taken 
at 490 nm. 
 
Recombinant protein and helicase assays   
Hi5 cells were infected with pVL132 K141/142A FANCJ and incubated for 72 hr.  Cells 
were collected, lysed in Insect Lysis Buffer (Roche) containing protease inhibitors 
(Roche) for 30 min at 4°C, and subsequently cleared by centrifugation.  The WT, K52R, 
and K141/142A FANCJ proteins were purified as previously described 6.  Briefly, 
K141/142A FANCJ-Flag was immunoprecipitated with 50 μl of FlagM2 conjugated 
beads for 2 hr at 40C.  Beads were washed three times in 500 mM NETN [ 500mM NaCl, 
0.5% NP-40, 1mM EDTA and 20 mM Tris-HCL (pH8.0)] followed by a final wash with 
150 mM NETN and K141/142A FANCJ protein was eluted twice using 3x Flag peptide.  
Elutions were pooled and dialyzed overnight in storage buffer.  Helicase assay reaction 
mixtures (20 µl) contained 40 mM Tris-HCl (pH 7.6), 25 mM KCl, 5 mM MgCl2, 2 mM 
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dithiothreitol, 2% glycerol, 100 ng/µl BSA, 2 mM ATP, 10 fmol of the specified duplex 
DNA substrate (0.5 nM DNA substrate concentration), and the indicated concentrations 
of FANCJ helicase.  Helicase reactions were initiated by the addition of FANCJ and then 
incubated at 30 oC for 15 min.  Reactions were quenched in the presence of a 10-fold 
excess of unlabeled oligonucleotide with the same sequence as the labeled strand to 
prevent reannealing and products resolved on nondenaturing 12% (19:1 acrylamide: 
bisacrylamide) polyacrylamide gels and quantitated as previously described 139. 
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CHAPTER V 
 
FINAL THOUGHTS AND FUTURE DIRECTIONS 
 
Environmental carcinogens and metabolic byproducts pose a constant threat to the 
genome and highlight the importance of the DNA damage response in maintaining 
genetic stability.  Not surprisingly, mutations in DNA damage response proteins like 
FANCJ can result in persistent damage and ultimately lead to the development of 
cancers.  However, this phenotype is not a ubiquitous phenomenon for mutations in all 
DNA damage response proteins.  Thus, I sought to identify how FANCJ participates in 
the DNA damage response pathway and why loss, and/or mutations in FANCJ lead to 
cellular transformation.  From my thesis research, we have demonstrated that FANCJ is a 
critical component of the DNA damage response pathway and loss of FANCJ leads to 
defects in HR, aberrant cell cycle progression, and genomic instability.  Furthermore, we 
identified germline mutations in FANCJ in patients with FA and solidified the role of 
FANCJ as a tumor suppressor.  Lastly, we have demonstrated that the FANCJ/BRCA1 
interaction and the FANCJ/MLH1 interaction serve to regulate distinct FANCJ functions.  
Disruption of the FANCJ/BRCA1 interaction causes a significant decrease in repair by 
HR.  However, loss of the FANCJ/MLH1 interaction disrupts normal cell cycle 
progression and sensitizes cells to MMC.  Taken together our data suggest FANCJ 
provides a novel link between the FA/BRCA and MMR pathways, expanding the role of  
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Figure 5-1: FANCJ functions.  Functions identified for the FANCJ helicase in the DNA 
damage response and tumor suppression. 
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FANCJ in genomic maintenance and emphasizing its significance in tumor suppression 
(Figure 5-1).  
Our initial studies on FANCJ demonstrated that FANCJ was a DNA damage 
response protein, which was phosphorylated following cellular exposure to DNA 
damaging agents.  The effects of DNA damage induced phosphorylation have been 
documented in several proteins including BRCA1, FANCD2, and the Werner helicase 
162,163.  Following exposure to IR, BRCA1 is phosphorylated at several residues and 
mutations that abolish phosphorylation at these specific sites cause cellular sensitivity to 
DNA damage, defects in cell cycle checkpoints, and/or delays in DNA damage repair 
kinetics.    Specifically, the DNA damage-induced phosphorylation of BRCA1 at S988 is 
critical for maintaining homologous recombinational repair.  Serine to Alanine point 
mutations at the S988 not only disrupt HR, but promote non-homologous end joining 164.  
Conceivably, DNA damage-induced phosphorylation of FANCJ could be central to 
FANCJ function.  Thus, it will be important to determine the kinase responsible for the 
phosphorylation(s) and at what site(s) the FANCJ protein is modified.  Moreover, it will 
be critical to understand how this phosphorylation may affect FANCJ DNA damage 
response.  We have provided evidence supporting a role for FANCJ in HR, thus it is 
plausible that the phosphorylation of FANCJ may contribute to homology directed repair.   
It is clear that maintaining homologous recombinational repair is essential to preserving 
the integrity of the genetic sequence.  Thus, mutations in FANCJ abrogating 
phosphorylation, may disrupt DNA damage repair, increase mutations, and ultimately, 
contribute to cancer development. 
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There is direct evidence linking FA/BRCA proteins to HR.  Specifically, in the 
absence of FA/BRCA proteins, including FANCA, FANCC, FANCD1, FANCD2, 
FANCJ, and BRCA1, homology directed DSB repair is diminished or disrupted.  Indirect 
evidence supporting FA/BRCA recombination function comes from the finding that these 
proteins are essential for crosslink repair, a process that requires HR.  Whether direct or 
indirect, FA/BRCA proteins respond to DNA damage and are essential for the ICL-repair 
response. Following ICL damage, the FA/BRCA pathway is activated and FANCD2 is 
monoubiquitinated by the FA core complex.  Activated FANCD2 translocates into 
chromatin and may help stabilize the replication fork to prevent replication fork collapse 
and/or illegitimate recombination.  Once stabilized, the fork can then be processed by the 
nucleotide excision repair and/or base excision repair machinery.  These repair pathways 
inevitably lead to the formation of a DSB, which must be repaired by HR to ensure that 
genetic information is not mutated or deleted.  Conceivably, the recruitment of repair 
factors to the site of the DSB may be initiated by FANCD2 monoubiquitination.  
BRCA1, FANCD1, and FANCJ have all been directly implicated in the HR repair 
process and have all been linked to an association with FANCD2.  These findings suggest 
that FANCD2 may not only mediate the DNA damage signal, but it may function as a 
molecular bridge between FA pathway activation and orchestration of the recombination 
process.   
While the core complex may function more indirectly in HR, these proteins 
should not be overlooked as they likely mediate the repair process.  For example, 
FANCG directly interacts was with the RAD51 paralog XRCC3.  XRCC3 is a key 
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component in the recombination repair pathway and facilitates the formation of the 
RAD51 nucleoprotein filament.  FANCG can be coprecipitated with both XRCC3 and 
BRCA2 and serves as a bridge stabilizing this ternary complex 41.  These findings 
highlight the importance of FANCG not only to FANCD2 monoubiquitination, but also 
following FANCD2 monoubiquitination during the early stages of recombination.  Thus, 
monoubiquitination of FANCD2 alone may not be sufficient to mediate the ICL response 
and coordinate repair.   The FA core complex is composed of 9 FA subunits and although 
they are critical for FANCD2 monoubiquitination, they have also demonstrated a role in 
mediating FANCD2 activity independent of FANCD2 monoubiquitination.  Specifically, 
a FANCD2 monoubiquitin fusion protein expressed in FA-C, FA-G, FA-D2, and FA-L 
cells failed to complement defects in MMC sensitivity or MMC-induced chromosomal 
breakage, but complemented these defects in FA-D2 cells.  These findings suggested the 
defects observed in FA-C, FA-G, and FA-L cells are not solely due to loss of FANCD2 
monoubiquitination, but underlying defects resulting from the loss of a subunit.  In fact, 
in addition to FANCD2 monoubiquitination, FA-C, FA-G, and FA-L are essential for 
targeting monoubiquitinated FANCD2 to chromatin and also regulating FANCD2 
function in chromatin for effective DNA repair 165.  Thus, the FA core complex appears 
to be critical not only for activation of the FA/BRCA pathway, but also for mediating 
ICL-induced repair processes.   
What remains unclear is if the FA core subunits are required for some aspect of 
the repair process, why HDR assays have produced conflicting results in some FA null 
cells.  Specifically, loss of FANCA and FANCC have both shown a reduction in HR 
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frequency by HDR assays, however, FANCC has also demonstrated normal HR repair.  
These conflicting HR results may be attributed to a more indirect role of these FA 
subunits in repair.  For example, it has been proposed that the FA core subunits may 
function to stabilize the replication fork at sites of damage, ultimately facilitating 
homologous recombination.  This hypothesis is supported by the finding that the FA core 
subunits have been observed in both chromatin fractions and also in foci containing 
FANCD2 following DNA damage.  Although the FA core complex is composed of 9 
subunits, many of the proteins form smaller subcomplexes.  For example, FANCA 
directly interacts with FANCG and forms a subcomplex with FANCB/FANCL/FANCM.  
Thus, suppression of FANCA may disrupt FANCD2 monoubiquitination, and assembly 
of the FANCA/G/B/L/M subcomplex, but leave other subcomplexes in tact.  As a result 
only the remaining subunits are left to stabilize the fork, compromising the integrity of 
recombination intermediates and framework of the repair machinery.  Consequently, only 
a portion of the replication forks are appropriately processed for recombination causing a 
partial reduction in HR.  Thus, the role of the core complex may be more dynamic then 
originally thought, extending beyond FA/BRCA pathway activation to homology directed 
repair. 
Although we have demonstrated a clear role for FANCJ in HR, it is unclear at 
which stage in recombination FANCJ functions.  In collaboration with Robert Brosh, we 
have shown that in vitro FANCJ unwinds D-loop recombination intermediates, yet it is 
unable to process HJ intermediates.  This feature is unique to FANCJ, as BLM and WRN 
DNA repair helicases have shown proficiency in processing HJ structures.  Conceivably, 
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FANCJ may bind D-loop structures to regulate homologous pairing of heteroduplex 
DNA during recombination.  The D-loop is the initial structure formed in recombination 
when the Rad51 nucleoprotein filament invades the duplex DNA in search of 
homologous repair-template.  Thus, Rad51 focal accumulation has been speculated to 
represent the development of these HR intermediates.  Suppression of either BRCA1 or 
FANCJ protein causes a cellular defect in HR, however, one difference observed between 
BRCA1 and FANCJ deficient cells is the visualization of Rad51 foci following DNA 
damage.  Suppression of BRCA1 results in loss of Rad51 foci formation, however, 
following suppression of FANCJ, robust Rad51 foci are readily observed. We speculate 
that the difference in Rad51 foci formation is a result of unregulated recombination.  In 
unperturbed cells both FANCJ and BRCA1 proteins are present and capable of 
coordinating HR, which we visualize as Rad51 foci.  In the absence of BRCA1, the 
FANCJ helicase becomes unregulated and disrupts the formation of recombination 
intermediates.  This disruption leads to inhibition of HR and consequently abolishes 
Rad51 foci formation.  In contrast, in the absence of FANCJ, HR is initiated, however, 
the process becomes unregulated and homologous heteroduplex DNA pairing is replaced 
by nonhomologous pairings resulting in illegitimate, or error prone, recombination.  This 
hypothesis is further supported by the interaction between FANCJ and the MMR protein 
MLH1.  MLH1 may function to regulate FANCJ helicase activity in mammalian cells as 
the E.coli homolog of MLH1, MutL, has been shown to regulate the E. coli helicase 
UvrD in vitro.  Therefore, we speculate that the interaction between BACH1 and MLH1 
is critical for regulating the stringency of recombination between heteroduplex DNA. 
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Taken together, we have proposed a model in which BRCA1 and MLH1 serve to regulate 
FANCJ helicase activity for efficient and accurate HR (Figure 5-2). 
            Our initial findings suggested that the S990A FANCJ mutant rescued both the 
MMC sensitivity and the ICL-induced 4N accumulation in FA-J cells.  However, more 
recently we found that disruption of the FANCJ/BRCA1 interaction disrupted HR in a 
homology directed repair assay.  Due to these potentially conflicting results, we looked 
more closely at the ability of the S990A FANCJ mutant to correct FA-J cells.  
Specifically, we analyzed the ICL-induced 4N accumulation in S990A FANCJ 
reconstituted FA-J cells over the course of 96 hours.  Although FA cells are characterized 
by a 4N accumulation at 72hrs following ICL treatment, both vector and WT FANCJ 
reconstituted FA-J cells also accumulate with 4N DNA content approximately 30 hrs 
after ICL treatment. However, the S990A FANCJ reconstituted FA-J cells did not 
accumulate with 4N DNA content at 30hrs following ICL treatment.  In fact, these cells 
did not accumulate with a 4N DNA content even at 96 hours following ICL damage.  
Contrary to our original findings, these data suggest that the S990A FANCJ mutant does 
not respond to ICL damage like WT FANCJ (Figure 5-3).   
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Figure 5-2: Model for FANCJ regulation in DNA repair.  We hypothesize that BRCA1 
and the MLH1/PMS2 proteins function to regulate FANCJ during recombination (see 
text for details). 
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 Adapted from Sung and Klein Nature Reviews Molecular Cell Biology 7, 739–750 (October 2006)  
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Figure 5-3: S990A FANCJ mutant does not correct defect in FA-J cell ICL response.  
FA-J cells were reconstituted with vector, WT FANCJ, or S990A FANCJ and cell cycle 
progression was analyzed for 96 hrs following treatment with melphalan.  A 
representative cell cycle profile is shown for untreated or 30hrs and 72hrs following 
treatment.    
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To further investigate this difference in ICL response between S990A FANCJ and 
WT FANCJ reconstituted cells, we analyzed the formation of both H2AX and RAD51 
foci following ICL damage.  Both WT FANCJ and S990A FANCJ reconstituted FA-J 
cells formed H2AX and RAD51 foci by 12hrs following ICL treatment.  In WT FANCJ 
reconstituted cells these foci dispersed to baseline levels by 72hrs following ICL 
treatment, however, in S990A FANCJ reconstituted FA-J cells both H2AX and RAD51 
foci returned to baseline levels by 48hrs.  Thus, it appears that the ICL response is 
initiated in both WT FANCJ and S990A FANCJ reconstituted FA-J cells, however, the 
S990A FANCJ mutant demonstrates different kinetics in response to ICL treatment.  
Conceivably, the differences in ICL response in the S990A FANCJ reconstituted FA-J 
cells could be explained as differences in types or rates of repair.  The early formation of 
RAD51 foci in the in both the WT FANCJ and S990A FANCJ reconstituted FA-J cells 
suggests that RAD51 mediated repair is initiated effectively.  However, the premature 
dispersal of both H2AX and RAD51 foci in the S990A FANCJ reconstituted  
FA-J cells suggest that repair is either completed faster, or by a repair mechanism 
independent of RAD51.  This hypothesis is supported by our initial findings that 
disruption of the FANCJ/BRCA1 interaction cause defects in HR.  Moreover, S990A 
FANCJ reconstituted FA-J cells are not sensitive to ICL damage suggesting that repair 
does in fact occur, but that this repair may be non-homologous.  It seems likely that 
disruption of the FANCJ/BRCA1 interaction disrupts HR, however, promotes an 
alternative type of repair such as SSA, NHEJ, or homeologous recombination.  We intend 
to quantitate the differences in ICL-induced 4N accumulation and H2AX and RAD51 
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foci formation observed in the S990A FANCJ reconstituted FA-J cells to validate our 
preliminary findings.  We have also initiated a collaboration with a recombination expert, 
Lisa Weismeuller, to analyze how disruption of the FANCJ/BRCA1 interaction affects 
various recombination substrates (i.e. SSA, NHEJ, and homeologous).        
Recombination is highly regulated process, however when it becomes 
unregulated, non-homologous DNA sequences are permitted during repair and as a result, 
the original DNA sequence can become mutated.  This unregulated recombination leads 
to genomic instability and can allow cancer cells to rapidly adapt to and bypass 
replication-blocking lesions generated by DNA damaging agents.  Thus, mutations in 
genes that regulate recombination can predispose cells to cancer and in some instances, 
make them resistant to chemical therapies that rely on replication blocking lesions for 
toxicity.  For example, loss of the MMR proteins is linked not only to hereditary colon 
cancer, but also to the acquired resistance of tumor cells to chemotherapy. While the 
mechanism of chemoresistance afforded by loss of MMR proteins is still largely 
unknown, it may be linked to unregulated hyper-recombination.  In support of this 
possibility, resistance of MMR-deficient yeast cells is dependent on recombination 
proteins RAD52 and RAD1166. If the hyper-recombinogenic phenotype is required for 
resistance of mammalian cells, inactivation of recombination could re-sensitize MMR-
deficient cancer cells to chemotherapy.  The goal of our future studies is to test whether 
inhibition of recombination in MMR deficient cells can restore their sensitivity to DNA 
damaging agents.  Furthermore, if hyper-recombination is universally required for the 
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development of chemoresistance, recombination inhibitors could have a major impact on 
the effective treatment of cancer. 
In conclusion, the studies presented in this thesis have had a major impact in our 
understanding of both the FA and MMR DNA damage response pathways and have 
encouraged future studies in this area.  In the past, basic mechanisms of DNA repair and 
DNA repair pathways were exploited in cancer cells to treat the cancer.  However, these 
therapies blanketed patients with several treatments in hopes that one would send the 
cancer into remission.  There is a growing interest in developing new cancer therapies 
tailored to meet the needs of each patient individually and has launched basic research 
into a new age of specifically targeted anti-cancer drugs.  It is our hope that the work 
presented here will contribute to the development of these treatments and ultimately the 
fight against cancer. 
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Appendix I 
 
In our model we propose that BRCA1 and MLH1 serve to regulate FANCJ during 
homologous recombination.  Thus, we predicted that disruption of either of these 
interactions would upset the equilibrium of the complex and ultimately, disrupt effective 
recombination.  The obvious difference between BRCA1 and FANCJ deficient cells is in 
the accumulation of Rad51 foci following DNA damage.  The presence of Rad51 foci 
visualized by immunofluorescence has been hypothesized to represent the formation of 
the Rad51 nucleoprotein filament during recombination.  We had already demonstrated 
that both BRCA1 and FANCJ were required for HR, however, it was unclear why Rad51 
foci accumulated in FANCJ, but not BRCA1 deficient cells.  Conceivably, BRCA1 
regulated FANCJ helicase activity during recombination.  For example, the assembly and 
disassembly of the Rad51 nucleoprotein filament is critical in the regulation of HR.  In S. 
cerevisiae the Srs2 helicase functions to strip Rad51 from the nucleoprotein filament 
preventing the early stages of HR. Similarly, we hypothesized that FANCJ functions to 
strip Rad51 from the nucleoprotein filament following strand invasion releasing Rad51 
for subsequent rounds of recombination.  Moreover, we predicted that this process was 
regulated by BRCA1.  Suppression of BRCA1 protein expression causes a significant 
decrease in the accumulation of Rad51 foci.  However, if the loss of Rad51 foci is due to 
unregulated FANCJ helicase activity, suppressing FANCJ in these cells would restore the 
appearance of Rad51 foci.  To test this hypothesis we created SKOV3 cells and 
suppressed EGFP, EGFP/BRCA1, or BRCA1/FANCJ, induced DNA damage, and 
quantitated the percentage of cells positive for Rad51 foci (> 5 foci ) by 
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immunofluorescence (Figure Ia).  We found that co-suppression of BRCA1 and FANCJ 
increased the percentage of Rad51 positive cells compared to suppression of BRCA1 
alone.  To further support these findings we reproduced these results in another cell line.  
We used FANCJ null FA-J cells and reconstituted them with empty vector, WT FANCJ, 
or S990A FANCJ (no BRCA1 binding).  As before, we induced DNA damage and 
quantitated the percentage of cells positive for Rad51 foci (Figure Ib). 
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Appendix II 
 
To determine whether FANCJ could strip Rad51 directly from ssDNA, we 
compared the ability of the WT FANCJ and the K52R mutant FANCJ to disassemble the 
Rad51 nucleoprotein filament in vitro.  This experiment was preformed as previously 
described (Fig IIa) 167.  Briefly, the 174 ssDNA was incubated with yeast Rad51 
(yRad51) protein for 5 minutes at 37°c.  In the experimental reactions, WT FANCJ, 
K52R FANCJ, or DNA helicase II was added and the reaction was incubated for another 
5 minutes at 37°c.  During this time, the capture strand was incubated with the 
streptavidin coated beads and then added to the initial reaction for a final 5 minutes.  The 
reaction was washed over a magnetic separator and the protein was eluted using SDS 
sample buffer.  Finally, the eluate was separated by SDS PAGE and analyzed by Western 
blot (Figure IIb right side).  We could recover greater then 50% of the yRad51 protein 
input on the capture strand and yRad51 protein did not stick to the streptavidin coated 
beads alone (Figure IIb left side).  The same experiment was repeated using human 
Rad51 protein (hRad51) and WT FANCJ, K52R FANCJ, and M299I FANCJ (Figure 
IIc).  The M299I mutation in FANCJ is a patient mutation which has demonstrated 
hyperactive helicase activity in vitro.  
We did not detect an increase in the amount of Rad51 (yeast or human) recovered 
on the capture strand when the nucleoprotein filament was incubated with FANCJ.  This 
suggested that the observed difference in Rad51 foci between BRCA1 and FANCJ 
deficient cells may not be attributed to disassembly of the Rad51 nucleoprotein filament.  
However, there are several potential caveats to this experiment.  First, we used yRad51 
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protein in these experiments because the yRad51 protein forms a highly stable interaction 
with the Φ174 ssDNA (Figure IIb right side lane 2).  However, we could not demonstrate 
that FANCJ functioned to strip the yeast Rad51 protein from ssDNA.  In hopes that the 
FANCJ protein required the human Rad51 protein in these experiments, we attempted to 
form a stable hRad51 nucleoprotein filament.  Unfortunately, the hRad51 nucleoprotein 
filament was not as stable as the yRad51 nucleoprotein filament and we observed an 
increase in the dissociation of the hRad51 protein from the Φ174 ssDNA (Figure IIc lane 
3).  This made it difficult to assess even small changes in Rad51 dissociation between the 
control and FANCJ containing reactions (Figure IIc compare lane 3 and lane 5).  Second, 
it’s possible that FANCJ requires a DNA damage signal or the association of other 
protein partners including, MLH1 and/or BRCA1 to displace Rad51 . 
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Appendix III 
 
Although FANCJ did not appear to disrupt the Rad51 nucleoprotein filament, we 
continued to investigate whether BRCA1 served to regulate FANCJ function.  If BRCA1 
regulates FANCJ during recombination, disruption of this interaction would result in a 
decrease in HR by our homology directed repair assay (chapter 3).  To disrupt the 
BRCA1/FANCJ interaction, we created a 46 amino acid FANCJ peptide that includes the 
region of FANCJ required for its interaction with BRCA1 (46 amino acid BRCA1 
Binding Domain - 46BBD) (Figure IIIa).  Both the empty TRX vector and the 46BBD 
were transfected into U20S cells and incubated for 48hrs.  The cells were lysed and the 
disruption of the FANCJ/BRCA1 complex was determined by FANCJ 
immunprecipitation and analyzed by Western blot (Figure IIIb).  Either empty TRX 
vector or 46BBD FANCJ peptide was transfected along with and the Sce-1 endonuclease 
into U20S cells containing the DR-GFP repair substrate and incubated for 72hrs.  The 
cells were collected and the percentage of GFP positive cells was analyzed by FACS. 
Error bars represent the standard deviation (Figure IIIc).    
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